NCTId;BriefTitle;LeadSponsorName;CollaboratorName;OverallStatus;StudyType;HasResults;StudyFirstPostDate;StartDate;CompletionDate;pmid;type;citation
NCT02014727;Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | BPRC | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme;COMPLETED;INTERVENTIONAL;False;2013-12-18;2014-01;2015-07;28947345;DERIVED;"Sirima SB, Durier C, Kara L, Houard S, Gansane A, Loulergue P, Bahuaud M, Benhamouda N, Nebie I, Faber B, Remarque E, Launay O; AMA1-DiCo Study Group. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. Vaccine. 2017 Oct 27;35(45):6218-6227. doi: 10.1016/j.vaccine.2017.09.027. Epub 2017 Sep 22."
NCT00117494;Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-07;2005-10;2007-06;22739396;DERIVED;"Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, Federspiel MC, Cherfils C, Costagliola D, Bonnefont-Rousselot D; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 126 study group. Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. AIDS. 2012 Sep 10;26(14):1801-5. doi: 10.1097/QAD.0b013e328357063c."
NCT00117494;Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-07;2005-10;2007-06;22318219;DERIVED;"Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, Fesel-Fouquier V, Costagliola D, Bonnefont-Rousselot D; ANRS 126 study group. Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. Antivir Ther. 2012;17(5):855-60. doi: 10.3851/IMP2065. Epub 2012 Feb 9."
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;16310901;BACKGROUND;"Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine. 2006 May 22;24(21):4482-9. doi: 10.1016/j.vaccine.2005.08.013. Epub 2005 Aug 18."
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;15382173;BACKGROUND;"Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004 Oct;40(4):874-82. doi: 10.1002/hep.20408."
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;24555998;DERIVED;"Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saidi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S; ANRS HB02 study group. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. Gut. 2015 Jan;64(1):139-47. doi: 10.1136/gutjnl-2013-305707. Epub 2014 Feb 20."
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;24394187;DERIVED;"Godon O, Fontaine H, Kahi S, Meritet JF, Scott-Algara D, Pol S, Michel ML, Bourgine M; ANRS HB02 study group. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther. 2014 Mar;22(3):675-684. doi: 10.1038/mt.2013.274. Epub 2013 Dec 5."
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;28708873;DERIVED;"Cheret A, Durier C, Melard A, Ploquin M, Heitzmann J, Lecuroux C, Avettand-Fenoel V, David L, Pialoux G, Chennebault JM, Muller-Trutwin M, Goujard C, Rouzioux C, Meyer L; ANRS OPTIPRIM study group. Impact of early cART on HIV blood and semen compartments at the time of primary infection. PLoS One. 2017 Jul 14;12(7):e0180191. doi: 10.1371/journal.pone.0180191. eCollection 2017."
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;25701561;DERIVED;"Cheret A, Nembot G, Melard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoen B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18."
NCT05349162;Epicardial vs. Transvenous ICDs in Children;Paris Cardiovascular Research Center (Inserm U970);Hôpital Necker-Enfants Malades;COMPLETED;OBSERVATIONAL;False;2022-04-27;2003-01-01;2022-04-01;;;
NCT01164462;Feasibility and Limitations of Offering Community Based Rapid HIV Testing to Men Who Have Sex With Men (MSM);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-07-16;2010-03;2011-04;;;
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33355914;DERIVED;"Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial). Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23."
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33010241;DERIVED;"Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngole E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1."
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;31339676;DERIVED;"NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24."
NCT00480792;Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients;ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2007-05-31;2007-06;2012-09;27064975;DERIVED;"Launay O, Rosenberg AR, Rey D, Pouget N, Michel ML, Reynes J, Neau D, Raffi F, Piroth L, Carrat F; ANRS HB03 VIHVAC-B (Trial Comparing 3 Strategies of Vaccination Against the Virus of Hepatitis B in HIV-Infected Patients) Group. Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med. 2016 May 1;176(5):603-10. doi: 10.1001/jamainternmed.2016.0741."
NCT00480792;Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients;ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2007-05-31;2007-06;2012-09;21486976;DERIVED;"Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdiere N, Slama L, Martin K, Lortholary O, Carrat F; ANRS HB03 VIHVAC-B Trial. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011 Apr 13;305(14):1432-40. doi: 10.1001/jama.2011.351."
NCT01095744;Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2010-03-30;2009-03;2012-05;;;
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;20169331;BACKGROUND;"Fatih N, Camberlein E, Island ML, Corlu A, Abgueguen E, Detivaud L, Leroyer P, Brissot P, Loreal O. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010 May;88(5):477-86. doi: 10.1007/s00109-009-0588-3. Epub 2010 Feb 19."
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;15974953;BACKGROUND;"Loreal O, Haziza-Pigeon C, Troadec MB, Detivaud L, Turlin B, Courselaud B, Ilyin G, Brissot P. Hepcidin in iron metabolism. Curr Protein Pept Sci. 2005 Jun;6(3):279-91. doi: 10.2174/1389203054065392."
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;16946298;BACKGROUND;"Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007 Jan 1;109(1):353-8. doi: 10.1182/blood-2006-07-033969. Epub 2006 Aug 31."
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;15501961;BACKGROUND;"Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004 Oct 15;10(20):6847-54. doi: 10.1158/1078-0432.CCR-04-0744."
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;18559556;BACKGROUND;"Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7. doi: 10.1158/1055-9965.EPI-07-2693."
NCT01453192;Renal Transplantation and Raltegravir in HIV-Infected Patients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-10-17;2011-12;2015-11;;;
NCT00460382;Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC | Janssen-Cilag Tibotec;COMPLETED;INTERVENTIONAL;False;2007-04-13;2007-05;2009-09;;;
NCT02486731;Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-01;2015-12-16;2018-12;;;
NCT02116374;Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-04-16;2014-12;2016-06;;;
NCT02497274;Obesity and Lipids: a Matter of Taste?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2016-01-11;2019-01;;;
NCT01022476;Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2009-12-01;2010-05;2013-05;;;
NCT00528060;Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada;French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2007-09-11;2008-01;2008-11;23459496;DERIVED;"Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentre F, Goujard C. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013 May;57(5):2265-71. doi: 10.1128/AAC.02605-12. Epub 2013 Mar 4."
NCT02078076;IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-05;2013-06;2015-11;;;
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27168667;BACKGROUND;"Blackburn NA, Patel RC, Zibbell JE. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014. Public Health Rep. 2016 May-Jun;131 Suppl 2(Suppl 2):91-7. doi: 10.1177/00333549161310S214."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;26806260;BACKGROUND;"Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hezode C, Pawlotsky JM. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect. 2016 May;22(5):459.e1-6. doi: 10.1016/j.cmi.2016.01.009. Epub 2016 Jan 22."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;22310560;BACKGROUND;"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;29432973;BACKGROUND;"Des Jarlais D, Khue PM, Feelemyer J, Arasteh K, Thi Huong D, Thi Hai Oanh K, Thi Giang H, Thi Tuyet Thanh N, Vinh VH, Heckathorn DD, Moles JP, Vallo R, Quillet C, Rapoud D, Michel L, Laureillard D, Hammett T, Nagot N. Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam. Drug Alcohol Depend. 2018 Apr 1;185:106-111. doi: 10.1016/j.drugalcdep.2017.11.033. Epub 2018 Feb 2."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27178119;BACKGROUND;"Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27537841;BACKGROUND;"Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;28004616;BACKGROUND;"Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, Chevaliez S, Pillonel J, Jauffret-Roustide M, LE Strat Y. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017 Apr;145(5):895-907. doi: 10.1017/S0950268816002934. Epub 2016 Dec 22."
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;35774932;DERIVED;"Nagot N, D'Ottavi M, Quillet C, Debellefontaine A, Castellani J, Langendorfer N, Hanslik B, Guichard S, Baglioni R, Faucherre V, Tuaillon E, Pageaux GP, Laureillard D, Donnadieu-Rigole H. Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C. Open Forum Infect Dis. 2022 Apr 14;9(6):ofac181. doi: 10.1093/ofid/ofac181. eCollection 2022 Jun."
NCT01331876;Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-04-08;2009-10;2012-07;;;
NCT00820820;IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis;Institut National de la Santé Et de la Recherche Médicale, France;Ministry of Health, France;COMPLETED;INTERVENTIONAL;False;2009-01-12;2009-01-09;2012-03-26;;;
NCT02273765;Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Ministry of Health, Brazil;COMPLETED;INTERVENTIONAL;False;2014-10-24;2015-09-11;2018-11-28;33667406;DERIVED;"De Castro N, Marcy O, Chazallon C, Messou E, Eholie S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B; ANRS 12300 Reflate TB2 study group. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2."
NCT02107365;Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO);ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2014-04-08;2013-11;2015-04;;;
NCT00113282;Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123);French National Agency for Research on AIDS and Viral Hepatitis;Chiron Corporation;COMPLETED;INTERVENTIONAL;False;2005-06-08;2004-06;2008-02;;;
NCT01055873;Immunology of the Infection Perinatal;French National Agency for Research on AIDS and Viral Hepatitis;Institut Pasteur | University of Paris 5 - Rene Descartes | Hôpital Necker-Enfants Malades;COMPLETED;OBSERVATIONAL;False;2010-01-26;2007-02;2009-02;22427678;DERIVED;"Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Riviere Y, Warszawski J, Rouzioux C, Buseyne F. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis. 2012 May 15;205(10):1520-8. doi: 10.1093/infdis/jis233. Epub 2012 Mar 15."
NCT05199831;Situational Analysis of HIV-related Disability in the Context of Ivory Coast;Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire;Institute of Research for Development, France | Institut de Sante Publique, d'Epidemiologie et de Developpement | University of Toronto | Université de Lille;COMPLETED;OBSERVATIONAL;False;2022-01-20;2021-02-05;2022-08-10;;;
NCT01359774;31P-MRS and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-05-25;2011-04;2012-04;21285522;BACKGROUND;"Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011 Feb;121(2):493-9. doi: 10.1172/JCI45691. Epub 2011 Feb 1."
NCT01359774;31P-MRS and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-05-25;2011-04;2012-04;17653274;BACKGROUND;"Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One. 2007 Jul 25;2(7):e647. doi: 10.1371/journal.pone.0000647."
NCT01359774;31P-MRS and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-05-25;2011-04;2012-04;21320997;BACKGROUND;"Mochel F, Benaich S, Rabier D, Durr A. Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Arch Neurol. 2011 Feb;68(2):265-7. doi: 10.1001/archneurol.2010.358. No abstract available."
NCT02099474;Evaluation of Raltegravir During the Third Trimester of Pregnancy;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-31;2014-06-30;2017-04;32661003;DERIVED;"Zheng Y, Hirt D, Delmas S, Lui G, Benaboud S, Lechedanec J, Treluyer JM, Chenevier-Gobeaux C, Arezes E, Gelley A, Amri I, Urien S, Bouazza N, Foissac F, Warszawski J, Ghosn J. Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00759-20. doi: 10.1128/AAC.00759-20. Print 2020 Sep 21."
NCT03546127;Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study;Institut National de la Santé Et de la Recherche Médicale, France;Institut Bergonié | Plateforme labellisée Inca - Institut Bergonié, Bordeaux | Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris | CNRGH, Evry | EUCLID Clinical Trial Platform;COMPLETED;OBSERVATIONAL;False;2018-06-06;2017-05-23;2017-09-21;;;
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32958495;BACKGROUND;"Ader F; Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34763056;BACKGROUND;"EU-Response investigators group; Diallo A, Troseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas JR, Baratt-Due A, Melien O, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentre F, Eustace J, Saillard J, Delmas C, LeMestre S, Dumousseaux M, Costagliola D, Rottingen JA, Yazdanpanah Y. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect. 2022 Jan;28(1):1-5. doi: 10.1016/j.cmi.2021.10.011. Epub 2021 Nov 8. No abstract available."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35623577;BACKGROUND;"Troseid M, Hentzien M, Ader F, Cardoso SW, Arribas JR, Molina JM, Mueller N, Hites M, Bonnet F, Manuel O, Costagliola D, Grinsztejn B, Olsen IC, Yazdapanah Y, Calmy A; EU RESPONSE; COMBINE. Immunocompromised patients have been neglected in COVID-19 trials: a call for action. Clin Microbiol Infect. 2022 Sep;28(9):1182-1183. doi: 10.1016/j.cmi.2022.05.005. Epub 2022 May 25. No abstract available."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36680782;BACKGROUND;"Terzic V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Troseid M, Demotes J, Olsen IC, Hites M, Ader F, Lopez JRA, Mentre F, Esperou H, Costagliola D, Rottingen JA, Poissy J, Roze JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A; EU-Response safety group; c4c safety group. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia. Br J Clin Pharmacol. 2023 Apr;89(4):1318-1328. doi: 10.1111/bcp.15669. Epub 2023 Feb 8."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36828006;BACKGROUND;"Amstutz A, Speich B, Mentre F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Muller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schonenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023 May;11(5):453-464. doi: 10.1016/S2213-2600(22)00528-8. Epub 2023 Feb 21. Erratum In: Lancet Respir Med. 2023 Aug;11(8):e77."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32473020;BACKGROUND;"Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, Yazdanpanah Y, Peytavin G. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020 Sep 1;75(9):2376-2380. doi: 10.1093/jac/dkaa191."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33089306;BACKGROUND;"Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, Yazdanpanah Y, Peytavin G; C-20-15 DisCoVeRy French Steering Committee. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response. J Antimicrob Chemother. 2021 Jan 1;76(1):277-279. doi: 10.1093/jac/dkaa415. No abstract available."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37269068;BACKGROUND;"Mercier N, Belhadi D, DeChanet A, Delmas C, Saillard J, Dumousseaux M, Le Mestre S, Fougerou-Leurent C, Ferrane A, Burdet C, Esperou H, Ader F, Hites M, Peiffer-Smadja N, Poissy J, Andrejak C, Paiva JA, Tacconelli E, Staub T, Greil R, Costagliola D, Mentre F, Yazdanpanah Y, Diallo A; DisCoVeRy Safety Working group. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial. Pharmacol Res Perspect. 2023 Jun;11(3):e01072. doi: 10.1002/prp2.1072."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37302469;BACKGROUND;"Fougerou-Leurent C, Delmas C, Saillard J, Dumousseaux M, Ferrane A, Mercier N, Terzic V, Le Mestre S, Dechanet A, Belhadi D, Metois A, Burdet C, Mentre F, Noret M, Diallo A, Petrov-Sanchez V, Couffin-Cadiergues S, Hites M, Ader F, Esperou H. Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study. Contemp Clin Trials. 2023 Aug;131:107267. doi: 10.1016/j.cct.2023.107267. Epub 2023 Jun 9."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33264556;RESULT;"WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernandez Garcia C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garcia PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portoles A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Rottingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34048876;RESULT;"Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabie A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Le MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F; DisCoVeRy study group. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34534511;RESULT;"Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Le MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35233617;RESULT;"Lingas G, Neant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentre F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412. doi: 10.1093/jac/dkac048."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35643099;RESULT;"Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentre F, Burdet C; DisCoVeRy Study Group. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infect Dis. 2022 Jun;22(6):764-765. doi: 10.1016/S1473-3099(22)00295-X. No abstract available."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35533972;RESULT;"Ader F; DisCoVeRy Study Group. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-beta-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results. Clin Microbiol Infect. 2022 Sep;28(9):1293-1296. doi: 10.1016/j.cmi.2022.04.016. Epub 2022 May 7. No abstract available."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37728045;RESULT;"Neant N, Lingas G, Gaymard A, Belhadi D, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Bouscambert-Duchamp M, Gagneux-Brunon A, Ader F, Mentre F, Wallet F, Burdet C, Guedj J; DisCoVeRy study group. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2027-2037. doi: 10.1002/psp4.13051. Epub 2023 Oct 11."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35512728;DERIVED;"WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2. Erratum In: Lancet. 2022 Oct 29;400(10362):1512. Lancet. 2024 Jan 13;403(10422):146."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34473343;DERIVED;"Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34350582;DERIVED;"Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962."
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32304640;DERIVED;"Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15. No abstract available."
NCT02987530;National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-12-09;2017-04-11;2020-01-31;;;
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;;;
NCT00122616;Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C;French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-07-22;2003-11;2009-03;23800784;DERIVED;"Chapplain JM, Bellissant E, Guyader D, Molina JM, Poizot-Martin I, Perre P, Pialoux G, Turlin B, Mouchel C, Renault A, Michelet C; ANRS HC-12 Study Group. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial. J Infect. 2013 Oct;67(4):313-21. doi: 10.1016/j.jinf.2013.05.007. Epub 2013 Jun 22."
NCT02428816;Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-29;2013-01-24;2016-07-28;;;
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24421886;BACKGROUND;"Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstrom J, Ljungman M, Torner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014 Jan 8;9(1):e83449. doi: 10.1371/journal.pone.0083449. eCollection 2014."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24793938;BACKGROUND;"Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi F, Mielcarek N, Locht C, Thorstensson R. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine. 2014 Jun 5;32(27):3350-6. doi: 10.1016/j.vaccine.2014.04.048. Epub 2014 Apr 29."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24950361;BACKGROUND;"Feunou PF, Kammoun H, Debrie AS, Locht C. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice. Vaccine. 2014 Jul 23;32(34):4281-8. doi: 10.1016/j.vaccine.2014.06.019. Epub 2014 Jun 17."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;22814407;BACKGROUND;"Kammoun H, Feunou PF, Foligne B, Debrie AS, Raze D, Mielcarek N, Locht C. Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice. Vaccine. 2012 Aug 31;30(40):5864-70. doi: 10.1016/j.vaccine.2012.07.005. Epub 2012 Jul 17."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21430219;BACKGROUND;"Fedele G, Bianco M, Debrie AS, Locht C, Ausiello CM. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol. 2011 May 1;186(9):5388-96. doi: 10.4049/jimmunol.1003765. Epub 2011 Mar 23."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21147936;BACKGROUND;"Skerry CM, Mahon BP. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol. 2011 Feb;18(2):187-93. doi: 10.1128/CVI.00371-10. Epub 2010 Dec 8."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20708998;BACKGROUND;"Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine. 2010 Oct 8;28(43):7047-53. doi: 10.1016/j.vaccine.2010.08.017. Epub 2010 Aug 13."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20419113;BACKGROUND;"Feunou PF, Bertout J, Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One. 2010 Apr 15;5(4):e10178. doi: 10.1371/journal.pone.0010178."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20107007;BACKGROUND;"Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol. 2010 Mar;17(3):317-24. doi: 10.1128/CVI.00322-09. Epub 2010 Jan 27."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;19625486;BACKGROUND;"Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, Mahon BP. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol. 2009 Sep;16(9):1344-51. doi: 10.1128/CVI.00082-09. Epub 2009 Jul 22."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;18762220;BACKGROUND;"Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008 Oct 23;26(45):5722-7. doi: 10.1016/j.vaccine.2008.08.018. Epub 2008 Aug 30."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;32687804;DERIVED;"Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, Thalen M, Solovay K, Rubin K, Mielcarek N, Thorstensson R, Locht C; BPZE1 study team. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect Dis. 2020 Nov;20(11):1290-1301. doi: 10.1016/S1473-3099(20)30274-7. Epub 2020 Jul 17. Erratum In: Lancet Infect Dis. 2020 Sep;20(9):e215."
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;31945015;DERIVED;"Lin A, Apostolovic D, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, van Hage M, Solovay K, Rubin K, Locht C, Thorstensson R, Thalen M, Lore K. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. J Clin Invest. 2020 May 1;130(5):2332-2346. doi: 10.1172/JCI135020."
NCT00120757;Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-19;2004-10;2008-11;22353022;DERIVED;"Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D; ANRS 120 Fosivir Study Group. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses. 2012 Sep;28(9):972-80. doi: 10.1089/AID.2011.0224. Epub 2012 Mar 23."
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29982518;DERIVED;"Vignier N, Dray Spira R, Pannetier J, Ravalihasy A, Gosselin A, Lert F, Lydie N, Bouchaud O, Desgrees Du Lou A, Chauvin P; PARCOURS Study Group. Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status. Eur J Public Health. 2018 Oct 1;28(5):904-910. doi: 10.1093/eurpub/cky118."
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29437866;DERIVED;"Gosselin A, Desgrees du Lou A, Lelievre E; PARCOURS Study Group. How to use sequence analysis for life course epidemiology? An example on HIV-positive Sub-Saharan migrants in France. J Epidemiol Community Health. 2018 Jun;72(6):507-512. doi: 10.1136/jech-2017-209739. Epub 2018 Feb 2."
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29307383;DERIVED;"Pannetier J, Ravalihasy A, Lydie N, Lert F, Desgrees du Lou A; Parcours study group. Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study. Lancet Public Health. 2018 Jan;3(1):e16-e23. doi: 10.1016/S2468-2667(17)30211-6. Epub 2017 Nov 23."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;17825642;BACKGROUND;"Kourtis AP, Jamieson DJ, de Vincenzi I, Taylor A, Thigpen MC, Dao H, Farley T, Fowler MG. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S113-22. doi: 10.1016/j.ajog.2007.03.003."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32991450;DERIVED;"Birungi N, Fadnes LT, Engebretsen IMS, Tumwine JK, Astrom AN; for ANRS 12174 AND 12341 study groups. Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial. Medicine (Baltimore). 2020 Sep 25;99(39):e22352. doi: 10.1097/MD.0000000000022352."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32228542;DERIVED;"Birungi N, Fadnes LT, Engebretsen IMS, Lie SA, Tumwine JK, Astrom AN; ANRS 12174 and 12341 study groups. Caries experience and oral health related quality of life in a cohort of Ugandan HIV-1 exposed uninfected children compared with a matched cohort of HIV unexposed uninfected children. BMC Public Health. 2020 Mar 30;20(1):423. doi: 10.1186/s12889-020-08564-1."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32067040;DERIVED;"Montoya-Ferrer A, Sanosyan A, Fayd'herbe de Maudave A, Pisoni A, Bollore K, Moles JP, Peries M, Tylleskar T, Tumwine JK, Ndeezi G, Gorgolas M, Nagot N, van de Perre P, Tuaillon E. Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda. Clin Infect Dis. 2021 Mar 15;72(6):1026-1032. doi: 10.1093/cid/ciaa161."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31994250;DERIVED;"Birungi N, Fadnes LT, Engebretsen IMS, Lie SA, Tumwine JK, Astrom AN; ANRS 12174 and 12341 study groups. Association of maternal HIV-1 severity with dental caries: an observational study of uninfected 5- to 7-yr-old children of HIV-1-infected mothers without severe immune suppression. Eur J Oral Sci. 2020 Feb;128(1):46-54. doi: 10.1111/eos.12669. Epub 2020 Jan 29."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31633158;DERIVED;"Kariyawasam D, Peries M, Foissac F, Eymard-Duvernay S, Tylleskar T, Singata-Madliki M, Kankasa C, Meda N, Tumwine J, Mwiya M, Engebretsen I, Fluck CE, Hartmann MF, Wudy SA, Hirt D, Treluyer JM, Moles JP, Blanche S, Van De Perre P, Polak M, Nagot N; ANRS 12174 Trial Group. Lopinavir-Ritonavir Impairs Adrenal Function in Infants. Clin Infect Dis. 2020 Aug 14;71(4):1030-1039. doi: 10.1093/cid/ciz888."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;30814028;DERIVED;"Blanche S, Tylleskar T, Peries M, Kankasa C, Engebretsen I, Meda N, Tumwine JK, Singata-Madliki M, Mwiya M, Van de Perre P, Nagot N; ANRS 12174 Trial Group. Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial. Lancet HIV. 2019 May;6(5):e307-e314. doi: 10.1016/S2352-3018(18)30361-8. Epub 2019 Feb 24."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;28469697;DERIVED;"Some EN, Engebretsen IMS, Nagot N, Meda N, Lombard C, Vallo R, Peries M, Kankasa C, Tumwine JK, Hofmeyr GJ, Singata M, Harper K, Van De Perre P, Tylleskar T; ANRS 12174 Trial Group. Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial. Int Breastfeed J. 2017 May 2;12:22. doi: 10.1186/s13006-017-0112-2. eCollection 2016."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;27895016;DERIVED;"Foissac F, Blume J, Treluyer JM, Tylleskar T, Kankasa C, Meda N, Tumwine JK, Singata-Madliki M, Harper K, Illamola SM, Bouazza N, Nagot N, Van de Perre P, Blanche S, Hirt D. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01869-16. doi: 10.1128/AAC.01869-16. Print 2017 Feb."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;26603917;DERIVED;"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Erratum In: Lancet. 2019 Jun 22;393(10190):2492."
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;23039034;DERIVED;"Nagot N, Kankasa C, Meda N, Hofmeyr J, Nikodem C, Tumwine JK, Karamagi C, Sommerfelt H, Neveu D, Tylleskar T, Van de Perre P; PROMISE-PEP group. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174. BMC Infect Dis. 2012 Oct 6;12:246. doi: 10.1186/1471-2334-12-246."
NCT01693835;"""Cancersensor"": Circadian Rhythms";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-08;2014-06;;;
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32070465;RESULT;"Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, Mechain M, Meurice L, Nguyen M, Bassi C, Yamani E, Behillil S, Ismael S, Nguyen D, Malvy D, Lescure FX, Georges S, Lazarus C, Tabai A, Stempfelet M, Enouf V, Coignard B, Levy-Bruhl D; Investigation team. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill. 2020 Feb;25(6):2000094. doi: 10.2807/1560-7917.ES.2020.25.6.2000094."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32224310;RESULT;"Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27. Erratum In: Lancet Infect Dis. 2020 May 19;: Lancet Infect Dis. 2020 Jun;20(6):e116."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32371096;RESULT;"Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020 Jun;55(6):106006. doi: 10.1016/j.ijantimicag.2020.106006. Epub 2020 May 3."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31978945;RESULT;"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32046819;RESULT;"Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020 Feb;25(5):2000062. doi: 10.2807/1560-7917.ES.2020.25.5.2000062."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31995857;RESULT;"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32109013;RESULT;"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28."
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32338732;RESULT;"Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston. JAMA. 2020 Jun 2;323(21):2191-2192. doi: 10.1001/jama.2020.6887."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26080690;BACKGROUND;"Elliott JC, Hasin DS, Stohl M, Des Jarlais DC. HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users. AIDS Behav. 2016 Mar;20(3):548-54. doi: 10.1007/s10461-015-1113-z."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26075647;BACKGROUND;"Perlman DC, Des Jarlais DC, Feelemyer J. Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis. 2015;34(2-3):198-205. doi: 10.1080/10550887.2015.1059111."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26050614;BACKGROUND;"Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, Des Jarlais DC. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015 Nov;26(11):1056-63. doi: 10.1016/j.drugpo.2015.04.015. Epub 2015 Apr 27."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26032121;BACKGROUND;"Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, Wiessing L, van de Laar M, Donoghoe M, Heckathorn DD, Friedman SR, Des Jarlais DC. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015 Sep;110(9):1453-67. doi: 10.1111/add.12999. Epub 2015 Jul 14."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;25540950;BACKGROUND;"Des Jarlais DC. AIDS, people who use drugs, and altruism: reflection on a personal image. Subst Use Misuse. 2015 Mar;50(4):532-3. doi: 10.3109/10826084.2015.978185. Epub 2014 Dec 26. No abstract available."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28800503;RESULT;"Michel L, Des Jarlais DC, Duong Thi H, Khuat Thi Hai O, Pham Minh K, Peries M, Vallo R, Nham Thi Tuyet T, Hoang Thi G, Le Sao M, Feelemyer J, Vu Hai V, Moles JP, Laureillard D, Nagot N; DRIVE Study Team. Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions. Drug Alcohol Depend. 2017 Oct 1;179:198-204. doi: 10.1016/j.drugalcdep.2017.07.004. Epub 2017 Aug 2."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27178119;RESULT;"Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27006257;RESULT;"Des Jarlais DC, Thi Huong D, Thi Hai Oanh K, Khue Pham M, Thi Giang H, Thi Tuyet Thanh N, Arasteh K, Feelemyer J, Hammett T, Peries M, Michel L, Vu Hai V, Roustide MJ, Moles JP, Laureillard D, Nagot N; DRIVE Study Team. Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam. Int J Drug Policy. 2016 Jun;32:50-6. doi: 10.1016/j.drugpo.2016.02.021. Epub 2016 Feb 27."
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28612212;RESULT;"Duong HT, Jarlais DD, Khuat OHT, Arasteh K, Feelemyer J, Khue PM, Giang HT, Laureillard D, Hai VV, Vallo R, Michel L, Moles JP, Nagot N; Drive Study Group. Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014. AIDS Behav. 2018 Jul;22(7):2161-2171. doi: 10.1007/s10461-017-1814-6."
NCT01693848;"""Cancersensor"" Metastasis Resection";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-09;2014-11;;;
NCT01895920;Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-11;2013-01;2018-02;;;
NCT01039220;Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2009-12-24;2009-12;2010-11;;;
NCT00820118;Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2009-01-09;2009-05;2012-05;26568566;DERIVED;"Piroth L, Moinot L, Yeni P, Avettand-Fenoel V, Reynes J, Girard PM, Marchou B, Georget A, Rouzioux C, Autran B, Duvillard L, Chene G, Fagard C; ANRS 141 TIPI Trial Study Group. Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). J Antimicrob Chemother. 2016 Feb;71(2):490-6. doi: 10.1093/jac/dkv369. Epub 2015 Nov 14."
NCT01801618;National Evaluation of PI-based 2nd Line Efficacy in Cambodia;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-03-01;2013-02;2014-12;;;
NCT02405013;Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-04-01;2015-10;2017-11;;;
NCT01779713;Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-02-04;2016-07-04;30354977;DERIVED;"Pulcrano-Nicolas AS, Proust C, Clarencon F, Jacquens A, Perret C, Roux M, Shotar E, Thibord F, Puybasset L, Garnier S, Degos V, Tregouet DA. Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage. Stroke. 2018 Sep;49(9):2220-2223. doi: 10.1161/STROKEAHA.118.021101."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;26762993;RESULT;"Frange P, Faye A, Avettand-Fenoel V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Saez-Cirion A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV. 2016 Jan;3(1):e49-54. doi: 10.1016/S2352-3018(15)00232-5. Epub 2015 Dec 9."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24945880;RESULT;"Aupiais C, Faye A, Le Chenadec J, Rouzioux C, Bouallag N, Laurent C, Blanche S, Dollfus C, Warszawski J; ANRS EPF-CO10 French Pediatric Cohort. Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children. Pediatr Infect Dis J. 2014 Dec;33(12):1237-45. doi: 10.1097/INF.0000000000000450."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24705410;RESULT;"Sofeu CL, Warszawski J, Ateba Ndongo F, Penda IC, Tetang Ndiang S, Guemkam G, Makwet N, Owona F, Kfutwah A, Tchendjou P, Texier G, Tchuente M, Faye A, Tejiokem MC; ANRS-PEDIACAM Study Group. Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon. PLoS One. 2014 Apr 3;9(4):e93554. doi: 10.1371/journal.pone.0093554. eCollection 2014."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24253249;RESULT;"Blanche S, Scott-Algara D, Le Chenadec J, Didier C, Montange T, Avettand-Fenoel V, Rouzioux C, Melard A, Viard JP, Dollfus C, Bouallag N, Warszawski J, Buseyne F. Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study. Clin Infect Dis. 2014 Feb;58(4):573-87. doi: 10.1093/cid/cit729. Epub 2013 Nov 18."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22427678;RESULT;"Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Riviere Y, Warszawski J, Rouzioux C, Buseyne F. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis. 2012 May 15;205(10):1520-8. doi: 10.1093/infdis/jis233. Epub 2012 Mar 15."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22198788;RESULT;"Goetghebuer T, Le Chenadec J, Haelterman E, Galli L, Dollfus C, Thorne C, Judd A, Keiser O, Ramos JT, Levy J, Warszawski J; European Infant Collaboration Group. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis. 2012 Mar;54(6):878-81. doi: 10.1093/cid/cir950. Epub 2011 Dec 23."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21971357;RESULT;"Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS. 2011 Nov 28;25(18):2279-87. doi: 10.1097/QAD.0b013e32834d614c."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21511330;RESULT;"Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011 May 7;377(9777):1580-7. doi: 10.1016/S0140-6736(11)60208-0. Epub 2011 Apr 20."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;20536367;RESULT;"Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, Warszawski J. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis. 2010 Jul 15;51(2):214-24. doi: 10.1086/653674."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;19194272;RESULT;"Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J; European Infant Collaboration group. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009 Mar 13;23(5):597-604. doi: 10.1097/QAD.0b013e328326ca37."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;18614870;RESULT;"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J. Response to combination antiretroviral therapy: variation by age. AIDS. 2008 Jul 31;22(12):1463-73. doi: 10.1097/QAD.0b013e3282f88d02."
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;17712765;RESULT;"Warszawski J, Lechenadec J, Faye A, Dollfus C, Firtion G, Meyer L, Douard D, Monpoux F, Tricoire J, Benmebarek Y, Rouzioux C, Blanche S. Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort. Clin Infect Dis. 2007 Sep 15;45(6):785-94. doi: 10.1086/521165. Epub 2007 Aug 14."
NCT03071458;Mutational Landscape in Hepatocellular Carcinoma;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-07;2008-01;2015-05;;;
NCT02886416;Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2016-09-01;2016-08;2017-04;;;
NCT01899196;Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-15;2013-07;2016-03;;;
NCT00944541;Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration;French National Agency for Research on AIDS and Viral Hepatitis;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-07-23;2009-09;2011-01;;;
NCT02160119;Emotional and Change-related Attention in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-06-10;2014-05-27;2018-05-27;;;
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16956918;BACKGROUND;"Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut. 2007 Aug;56(8):1105-10. doi: 10.1136/gut.2006.091983. Epub 2006 Sep 6."
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16847958;BACKGROUND;"Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, Anwar M, Attala M, Rekacewicz C, Zalata K, Abdel-Hamid M, Esmat G, Fontanet A. HCV-related morbidity in a rural community of Egypt. J Med Virol. 2006 Sep;78(9):1185-9. doi: 10.1002/jmv.20679."
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16434426;BACKGROUND;"Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut. 2006 Aug;55(8):1183-7. doi: 10.1136/gut.2005.078147. Epub 2006 Jan 24."
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16019104;BACKGROUND;"Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A. Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol. 2005 Sep;43(3):418-24. doi: 10.1016/j.jhep.2005.03.021."
NCT02192658;Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Handicap International | Institut de Recherche pour le Developpement | Institut de Formation et de Recherche Démographique | Forum Camerounais de Psychologie | Centre de Recherche Internationale pour la Santé de l'Université de Ouagadougou;COMPLETED;OBSERVATIONAL;False;2014-07-17;2014-11;2016-07;26846895;DERIVED;"De Beaudrap P, Pasquier E, Tchoumkeu A, Touko A, Essomba F, Brus A, Desgrees du Lou A, Aderemi TJ, Hanass-Hancock J, Eide AH, Mont D, Mac-Seing M, Beninguisse G. HandiVIH--A population-based survey to understand the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations. BMJ Open. 2016 Feb 4;6(2):e008934. doi: 10.1136/bmjopen-2015-008934."
NCT00383734;Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE;French National Agency for Research on AIDS and Viral Hepatitis;Procitech | Sanofi;COMPLETED;INTERVENTIONAL;False;2006-10-03;2006-12;2010-09;23432777;DERIVED;"Lafaurie M, Dolivo M, Girard PM, May T, Bouchaud O, Carbonnel E, Madelaine I, Loze B, Porcher R, Molina JM; ANRS 132 SMILE study group. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) 132 SMILE]. HIV Med. 2013 Aug;14(7):410-20. doi: 10.1111/hiv.12021. Epub 2013 Feb 24."
NCT02051413;Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-31;2014-02-18;2018-05;;;
NCT03109067;Genetic and Metabolism of Post-prandial HDL Particles;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-04-12;2011-09-21;2015-11-21;;;
NCT02073604;Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-03;2016-02;;;
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;17531315;RESULT;"Hoffmann P, Feige JJ, Alfaidy N. Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation. Placenta. 2007 Oct;28(10):1049-58. doi: 10.1016/j.placenta.2007.03.008. Epub 2007 May 25."
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;16384869;RESULT;"Hoffmann P, Feige JJ, Alfaidy N. Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology. 2006 Apr;147(4):1675-84. doi: 10.1210/en.2005-0912. Epub 2005 Dec 29."
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;19602057;RESULT;"Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazouni C, Feige JJ, Alfaidy N. Role of EG-VEGF in human placentation: Physiological and pathological implications. J Cell Mol Med. 2009 Aug;13(8B):2224-2235. doi: 10.1111/j.1582-4934.2008.00554.x."
NCT01335529;Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin;ANRS, Emerging Infectious Diseases;Rennes University Hospital | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-04-14;2011-05;2014-05;27077673;DERIVED;"Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourliere M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11."
NCT00545194;Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-10-17;2002-01;2004-10;11236117;BACKGROUND;"Lyrenas S, Clason I, Ulmsten U. In vivo controlled release of PGE2 from a vaginal insert (0.8 mm, 10 mg) during induction of labour. BJOG. 2001 Feb;108(2):169-78. doi: 10.1111/j.1471-0528.2001.00039.x."
NCT00545194;Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-10-17;2002-01;2004-10;16553177;BACKGROUND;"Strobelt N, Meregalli V, Ratti M, Mariani S, Zani G, Morana S. Randomized study on removable PGE2 vaginal insert versus PGE2 cervical gel for cervical priming and labor induction in low-Bishop-score pregnancy. Acta Obstet Gynecol Scand. 2006;85(3):302-5. doi: 10.1080/00016340500523685."
NCT00545194;Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-10-17;2002-01;2004-10;17071427;BACKGROUND;"El-Shawarby SA, Connell RJ. Induction of labour at term with vaginal prostaglandins preparations: a randomised controlled trial of Prostin vs Propess. J Obstet Gynaecol. 2006 Oct;26(7):627-30. doi: 10.1080/01443610600903362."
NCT03298360;A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-10-02;2018-06-28;2020-06-25;;;
NCT01508494;Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-01-12;2011-06-29;2016-06-22;;;
NCT00573001;Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA);French National Agency for Research on AIDS and Viral Hepatitis;Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-12-13;2008-07;2011-12;;;
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;14770396;BACKGROUND;"Leung WC, Jouannic JM, Hyett J, Rodeck C, Jauniaux E. Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios. Ultrasound Obstet Gynecol. 2004 Feb;23(2):154-8. doi: 10.1002/uog.972."
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;11438952;BACKGROUND;"Jauniaux E, Holmes A, Hyett J, Yates R, Rodeck C. Rapid and radical amniodrainage in the treatment of severe twin-twin transfusion syndrome. Prenat Diagn. 2001 Jun;21(6):471-6. doi: 10.1002/pd.96."
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;7970458;BACKGROUND;"Elliott JP, Sawyer AT, Radin TG, Strong RE. Large-volume therapeutic amniocentesis in the treatment of hydramnios. Obstet Gynecol. 1994 Dec;84(6):1025-7."
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;9464739;BACKGROUND;"Dolinger MB, Donnenfeld AE. Therapeutic amniocentesis using a vacuum bottle aspiration system. Obstet Gynecol. 1998 Jan;91(1):143-4. doi: 10.1016/s0029-7844(97)00584-x."
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;34874888;DERIVED;"van Genugten CR, Schuurmans J, Hoogendoorn AW, Araya R, Andersson G, Banos R, Botella C, Cerga Pashoja A, Cieslak R, Ebert DD, Garcia-Palacios A, Hazo JB, Herrero R, Holtzmann J, Kemmeren L, Kleiboer A, Krieger T, Smoktunowicz E, Titzler I, Topooco N, Urech A, Smit JH, Riper H. Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study. JMIR Ment Health. 2021 Dec 6;8(12):e32007. doi: 10.2196/32007."
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;27488181;DERIVED;"Kleiboer A, Smit J, Bosmans J, Ruwaard J, Andersson G, Topooco N, Berger T, Krieger T, Botella C, Banos R, Chevreul K, Araya R, Cerga-Pashoja A, Cieslak R, Rogala A, Vis C, Draisma S, van Schaik A, Kemmeren L, Ebert D, Berking M, Funk B, Cuijpers P, Riper H. European COMPARative Effectiveness research on blended Depression treatment versus treatment-as-usual (E-COMPARED): study protocol for a randomized controlled, non-inferiority trial in eight European countries. Trials. 2016 Aug 3;17(1):387. doi: 10.1186/s13063-016-1511-1."
NCT03671291;Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV;French National Agency for Research on AIDS and Viral Hepatitis;University Hospital, Marseille | University Hospital, Grenoble | Centre Hospitalier Universitaire de Nice | University Hospital, Montpellier | Hospital Purpan | University Hospital, Bordeaux | Hôpital de la Croix-Rousse | Centre Hospitalier Universitaire Dijon | University Hospital of Saint-Etienne | University Hospital, Clermont-Ferrand | Centre Hospitalier Universitaire de Besancon | Tourcoing Hospital | University Hospital, Strasbourg | Nantes University Hospital | Centre Hospitalier Régional d'Orléans | Rennes University Hospital | Saint Antoine University Hospital | Tenon Hospital, Paris | Saint-Louis Hospital, Paris, France | Hôpital Necker-Enfants Malades | Bicetre Hospital | Pitié-Salpêtrière Hospital | Bichat Hospital | University Hospital Center of Martinique;COMPLETED;INTERVENTIONAL;False;2018-09-14;2019-04-03;2021-10-03;;;
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;33794182;DERIVED;"Esteban-Cantos A, Rodriguez-Centeno J, Barruz P, Alejos B, Saiz-Medrano G, Nevado J, Martin A, Gaya F, De Miguel R, Bernardino JI, Montejano R, Mena-Garay B, Cadinanos J, Florence E, Mulcahy F, Banhegyi D, Antinori A, Pozniak A, Wallet C, Raffi F, Rodes B, Arribas JR; NEAT001/ANRS143 Study Group. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2021 Apr;8(4):e197-e205. doi: 10.1016/S2352-3018(21)00006-0. Erratum In: Lancet HIV. 2021 Dec;8(12):e734."
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;30365452;DERIVED;"Ammassari A, Stohr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; NEAT001/ANRS143 Trial Study Group. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):481-490. doi: 10.1097/QAI.0000000000001834."
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;26520926;DERIVED;"Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buno A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30."
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;25103176;DERIVED;"Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chene G, Pozniak A; NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4."
NCT01703962;Non Invasive IDentification of Gliomas With IDH1 Mutation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-11;2012-03-14;2014-03-20;;;
NCT03642704;HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-08-22;2017-02-22;2019-09-17;;;
NCT01086904;Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients;Institut National de la Santé Et de la Recherche Médicale, France;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2010-03-15;2009-11;2010-05;;;
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;34723858;DERIVED;"Pressiat C, Toni TD, Treluyer JM, Yonaba C, Dahourou DL, Malateste K, Seguin-Devaux C, Leroy V, Hirt D; MONOD ANRS Study Group. High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy. AIDS. 2021 Nov 15;35(14):2409-2410. doi: 10.1097/QAD.0000000000003043. No abstract available."
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;31334298;DERIVED;"Desmonde S, Frank SC, Coovadia A, Dahourou DL, Hou T, Abrams EJ, Amorissani-Folquet M, Walensky RP, Strehlau R, Penazzato M, Freedberg KA, Kuhn L, Leroy V, Ciaranello AL. Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus. Open Forum Infect Dis. 2019 Jun 11;6(7):ofz276. doi: 10.1093/ofid/ofz276. eCollection 2019 Jul."
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28800382;DERIVED;"Pressiat C, Mea-Assande V, Yonaba C, Treluyer JM, Dahourou DL, Amorissani-Folquet M, Blanche S, Eboua F, Ye D, Lui G, Malateste K, Zheng Y, Leroy V, Hirt D; MONOD Study Group. Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines. Br J Clin Pharmacol. 2017 Dec;83(12):2729-2740. doi: 10.1111/bcp.13397. Epub 2017 Sep 20."
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28483965;DERIVED;"Pressiat C, Amorissani-Folquet M, Yonaba C, Treluyer JM, Dahourou DL, Eboua F, Blanche S, Mea-Assande V, Bouazza N, Foissac F, Malateste K, Ouedraogo S, Lui G, Leroy V, Hirt D. Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00297-17. doi: 10.1128/AAC.00297-17. Print 2017 Jul."
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28453240;DERIVED;"Amani-Bosse C, Dahourou DL, Malateste K, Amorissani-Folquet M, Coulibaly M, Dattez S, Emieme A, Barry M, Rouzioux C, N'gbeche S, Yonaba C, Timite-Konan M, Mea V, Ouedraogo S, Blanche S, Meda N, Seguin-Devaux C, Leroy V. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. J Int AIDS Soc. 2017 Apr 25;20(1):21362. doi: 10.7448/IAS.20.01.21362."
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28434406;DERIVED;"Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouedraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouedraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timite-Konan M, Leroy V; MONOD Study Group. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Cote d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. BMC Med. 2017 Apr 24;15(1):85. doi: 10.1186/s12916-017-0842-4."
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;27015798;DERIVED;"Dahourou DL, Amorissani-Folquet M, Coulibaly M, Avit-Edi D, Meda N, Timite-Konan M, Arendt V, Ye D, Amani-Bosse C, Salamon R, Lepage P, Leroy V; Monod Anrs 12206 Study Group. Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013. J Int AIDS Soc. 2016 Mar 23;19(1):20601. doi: 10.7448/IAS.19.1.20601. eCollection 2016."
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;30081838;DERIVED;"Cames C, Pascal L, Ba A, Mbodj H, Ouattara B, Diallo NF, Msellati P, Mbaye N, Sy Signate H, Blanche S, Diack A; MAGGSEN Cohort Study Group. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study. BMC Infect Dis. 2018 Aug 6;18(1):374. doi: 10.1186/s12879-018-3282-7."
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;27881690;DERIVED;"Cames C, Varloteaux M, Have NN, Diom AB, Msellati P, Mbaye N, Mbodj H, Sy Signate H, Diack A; ANRS 12279 MAGGSEN Cohort Study Group. Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study. Food Nutr Bull. 2017 Mar;38(1):27-36. doi: 10.1177/0379572116679053. Epub 2016 Nov 23."
NCT00196612;Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART;French National Agency for Research on AIDS and Viral Hepatitis;Triangle Pharmaceuticals | Gilead Sciences | Bristol-Myers Squibb | Dupont Applied Biosciences;COMPLETED;INTERVENTIONAL;False;2005-09-20;2001-04;2004-09;15717256;RESULT;"Molina JM, Journot V, Morand-Joubert L, Yeni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis. 2005 Mar 15;191(6):830-9. doi: 10.1086/428091. Epub 2005 Feb 10."
NCT01226446;Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-10-22;2010-11;2013-01;25987791;DERIVED;"Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, Thibault V, Souberbielle JC, Carrat F, Cacoub P. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J Gastroenterol. 2015 May 14;21(18):5647-53. doi: 10.3748/wjg.v21.i18.5647."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;12461757;BACKGROUND;"Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, Caci H, Borg M, Brocker P, Bedoucha P. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002 Dec;17(12):1099-105. doi: 10.1002/gps.755."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10436334;BACKGROUND;"Pasquier F, Lebert F, Lavenu I, Guillaume B. The clinical picture of frontotemporal dementia: diagnosis and follow-up. Dement Geriatr Cogn Disord. 1999;10 Suppl 1:10-4. doi: 10.1159/000051206."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19713543;BACKGROUND;"Mayo NE, Fellows LK, Scott SC, Cameron J, Wood-Dauphinee S. A longitudinal view of apathy and its impact after stroke. Stroke. 2009 Oct;40(10):3299-307. doi: 10.1161/STROKEAHA.109.554410. Epub 2009 Aug 27."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17027767;BACKGROUND;"Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull. 2006 Oct 16;70(4-6):312-21. doi: 10.1016/j.brainresbull.2006.06.007. Epub 2006 Jul 5."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10678322;BACKGROUND;"Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994 Apr;182(4):235-9. doi: 10.1097/00005053-199404000-00008."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;18307266;BACKGROUND;"Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. The Lille Apathy Rating Scale: validation of a caregiver-based version. Mov Disord. 2008 Apr 30;23(6):845-9. doi: 10.1002/mds.21968."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19533496;BACKGROUND;"Lane-Brown AT, Tate RL. Apathy after acquired brain impairment: a systematic review of non-pharmacological interventions. Neuropsychol Rehabil. 2009 Aug;19(4):481-516. doi: 10.1080/09602010902949207."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;15897497;BACKGROUND;"Czernecki V, Pillon B, Houeto JL, Welter ML, Mesnage V, Agid Y, Dubois B. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):775-9. doi: 10.1136/jnnp.2003.033258."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19933975;BACKGROUND;"Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S, Sauleau P, Haegelen C, Travers D, Garin E, Malbert CH, Millet B, Verin M. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009 Nov 24;73(21):1746-51. doi: 10.1212/WNL.0b013e3181c34b34."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;1821241;BACKGROUND;"Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):243-54. doi: 10.1176/jnp.3.3.243."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16207933;BACKGROUND;"Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006 Jul;16(7):916-28. doi: 10.1093/cercor/bhj043. Epub 2005 Oct 5."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17131230;BACKGROUND;"Levy R, Czernecki V. Apathy and the basal ganglia. J Neurol. 2006 Dec;253 Suppl 7:VII54-61. doi: 10.1007/s00415-006-7012-5."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10941190;BACKGROUND;"Brown RG, Pluck G. Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci. 2000 Sep;23(9):412-7. doi: 10.1016/s0166-2236(00)01626-x."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16421064;BACKGROUND;"Muller U, Czymmek J, Thone-Otto A, Von Cramon DY. Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy. Brain Inj. 2006 Feb;20(2):157-60. doi: 10.1080/02699050500443467."
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;21895376;BACKGROUND;"Funkiewiez A, Bertoux M, de Souza LC, Levy R, Dubois B. The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. Neuropsychology. 2012 Jan;26(1):81-90. doi: 10.1037/a0025318. Epub 2011 Sep 5."
NCT04133012;Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone;ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2019-10-21;2020-02-10;2023-06-09;;;
NCT01100281;Prefrontal Cortex and Abstract Thinking;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2010-04-08;2010-04;2011-04;;;
NCT01647295;Social Interactions: Ocular Explorations and Pupillometry in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-07-23;2013-02-25;2019-06-18;;;
NCT00424814;Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva;ANRS, Emerging Infectious Diseases;Abbott;COMPLETED;INTERVENTIONAL;False;2007-01-22;2007-03;2012-11;25838291;DERIVED;"Sibiude J, Le Chenadec J, Bonnet D, Tubiana R, Faye A, Dollfus C, Mandelbrot L, Delmas S, Lelong N, Khoshnood B, Warszawski J, Blanche S; French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial. In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial. Clin Infect Dis. 2015 Jul 15;61(2):270-80. doi: 10.1093/cid/civ260. Epub 2015 Apr 1."
NCT00424814;Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva;ANRS, Emerging Infectious Diseases;Abbott;COMPLETED;INTERVENTIONAL;False;2007-01-22;2007-03;2012-11;23766338;DERIVED;"Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group. Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial. Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12."
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;22639796;RESULT;"Marino RA, Levy R, Boehnke S, White BJ, Itti L, Munoz DP. Linking visual response properties in the superior colliculus to saccade behavior. Eur J Neurosci. 2012 Jun;35(11):1738-52. doi: 10.1111/j.1460-9568.2012.08079.x. Epub 2012 May 28."
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;6774653;RESULT;"Wurtz RH, Albano JE. Visual-motor function of the primate superior colliculus. Annu Rev Neurosci. 1980;3:189-226. doi: 10.1146/annurev.ne.03.030180.001201. No abstract available."
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;23916713;RESULT;"Rolland M, Carcenac C, Overton PG, Savasta M, Coizet V. Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease. Neuroscience. 2013 Nov 12;252:277-88. doi: 10.1016/j.neuroscience.2013.07.047. Epub 2013 Jul 31."
NCT00658346;Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2008-04-15;2010-06;2016-09;31063537;DERIVED;"Kouanfack C, Unal G, Schaeffer L, Kfutwah A, Aghokeng A, Mougnutou R, Tchemgui-Noumsi N, Alessandri-Gradt E, Delaporte E, Simon F, Vray M, Plantier JC; ANRS 12168 DynaMO Study. Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients. Clin Infect Dis. 2020 Mar 17;70(7):1471-1477. doi: 10.1093/cid/ciz371."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;16839199;BACKGROUND;"Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2006 Jul;2(7):e65. doi: 10.1371/journal.ppat.0020065."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;18762220;BACKGROUND;"Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008 Oct 23;26(45):5722-7. doi: 10.1016/j.vaccine.2008.08.018. Epub 2008 Aug 30."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;20107007;BACKGROUND;"Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol. 2010 Mar;17(3):317-24. doi: 10.1128/CVI.00322-09. Epub 2010 Jan 27."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;20184606;BACKGROUND;"Kavanagh H, Noone C, Cahill E, English K, Locht C, Mahon BP. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy. 2010 Jun;40(6):933-41. doi: 10.1111/j.1365-2222.2010.03459.x. Epub 2010 Feb 22."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;19625486;BACKGROUND;"Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, Mahon BP. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol. 2009 Sep;16(9):1344-51. doi: 10.1128/CVI.00082-09. Epub 2009 Jul 22."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;24793938;DERIVED;"Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi F, Mielcarek N, Locht C, Thorstensson R. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine. 2014 Jun 5;32(27):3350-6. doi: 10.1016/j.vaccine.2014.04.048. Epub 2014 Apr 29."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;24421886;DERIVED;"Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstrom J, Ljungman M, Torner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014 Jan 8;9(1):e83449. doi: 10.1371/journal.pone.0083449. eCollection 2014."
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;24261996;DERIVED;"Schnoeller C, Roux X, Sawant D, Raze D, Olszewska W, Locht C, Openshaw PJ. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med. 2014 Jan 15;189(2):194-202. doi: 10.1164/rccm.201307-1227OC."
NCT04945655;Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-06-30;2021-11-15;2023-04-30;35332045;DERIVED;"Bocquier A, Michel M, Giraudeau B, Bonnay S, Gagneux-Brunon A, Gauchet A, Gilberg S, Le Duc-Banaszuk AS, Mueller JE, Chevreul K, Thilly N; PrevHPV Study group. Impact of a school-based and primary care-based multicomponent intervention on HPV vaccination coverage among French adolescents: a cluster randomised controlled trial protocol (the PrevHPV study). BMJ Open. 2022 Mar 24;12(3):e057943. doi: 10.1136/bmjopen-2021-057943."
NCT01942655;IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-16;2014-06-01;2018-03-01;;;
NCT01332955;Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen;ANRS, Emerging Infectious Diseases;Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2011-04-11;2011-04;2013-09;25139963;DERIVED;"Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18."
NCT01552044;Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-03-13;2012-01;2013-02;;;
NCT02592174;Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2015-10-30;2016-01-26;2017-10-27;31755936;DERIVED;"Makinson A, Dubois J, Eymard-Duvernay S, Leclercq P, Zaegel-Faucher O, Bernard L, Vassallo M, Barbuat C, Geny C, Thouvenot E, Costagliola D, Ozguler A, Zins M, Simony M, Reynes J, Berr C. Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study. Clin Infect Dis. 2020 Jun 10;70(12):2641-2648. doi: 10.1093/cid/ciz670."
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;21957063;BACKGROUND;"Borel P. Genetic variations involved in interindividual variability in carotenoid status. Mol Nutr Food Res. 2012 Feb;56(2):228-40. doi: 10.1002/mnfr.201100322. Epub 2011 Sep 29."
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;27798339;DERIVED;"Desmarchelier C, Borel P, Goncalves A, Kopec R, Nowicki M, Morange S, Lesavre N, Portugal H, Reboul E. A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Cholecalciferol Bioavailability in Healthy Men. J Nutr. 2016 Dec;146(12):2421-2428. doi: 10.3945/jn.116.237115. Epub 2016 Oct 26."
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;26063065;DERIVED;"Borel P, Desmarchelier C, Nowicki M, Bott R. A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary beta-Carotene Bioavailability in Healthy Men. J Nutr. 2015 Aug;145(8):1740-7. doi: 10.3945/jn.115.212837. Epub 2015 Jun 10."
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;24808487;DERIVED;"Borel P, Desmarchelier C, Nowicki M, Bott R, Morange S, Lesavre N. Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with fasting plasma lutein concentration. Am J Clin Nutr. 2014 Jul;100(1):168-75. doi: 10.3945/ajcn.114.085720. Epub 2014 May 7."
NCT00490074;Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;EuroVacc Foundation;COMPLETED;INTERVENTIONAL;False;2007-06-22;2007-07;2009-10;;;
NCT01882062;Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2013-06-20;2013-05;2013-07;25568297;RESULT;"Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, Mochel F. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015 Feb 3;84(5):490-5. doi: 10.1212/WNL.0000000000001214. Epub 2015 Jan 7."
NCT01525472;Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-03;2012-02-13;2015-10-20;;;
NCT02650427;A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-08;2016-02;2018-09;;;
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;31784343;DERIVED;"Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM; ANRS IPERGAY study group. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020 Feb;7(2):e113-e120. doi: 10.1016/S2352-3018(19)30341-8. Epub 2019 Nov 26."
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;29229440;DERIVED;"Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bebear C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Dore V, Meyer L; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8."
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;28747274;DERIVED;"Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Dore V, Meyer L; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23."
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;26624850;DERIVED;"Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Preau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Dore V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1."
NCT02267304;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-10-17;2013-10-30;2016-08-30;;;
NCT04780191;Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke;Institut National de la Santé Et de la Recherche Médicale, France;PathMaker Neurosystems Inc.;COMPLETED;INTERVENTIONAL;False;2021-03-03;2018-07-19;2021-01-19;32232101;BACKGROUND;"Paget-Blanc A, Chang JL, Saul M, Lin R, Ahmed Z, Volpe BT. Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation. Bioelectron Med. 2019 Jul 23;5:11. doi: 10.1186/s42234-019-0028-9. eCollection 2019."
NCT00495326;Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO);French National Agency for Research on AIDS and Viral Hepatitis;Medecins Sans Frontieres, Netherlands;COMPLETED;INTERVENTIONAL;False;2007-07-03;2007-12;2011-04;24663014;DERIVED;"Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM; ANRS 12146-CARINEMO Study Group. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24."
NCT00495326;Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO);French National Agency for Research on AIDS and Viral Hepatitis;Medecins Sans Frontieres, Netherlands;COMPLETED;INTERVENTIONAL;False;2007-07-03;2007-12;2011-04;23433590;DERIVED;"Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A; CARINEMO study group. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis. 2013 Apr;13(4):303-12. doi: 10.1016/S1473-3099(13)70007-0. Epub 2013 Feb 20."
NCT03459157;Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP);ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | Institut de Médecine Tropicale, Anvers, Belgique | ARCAD-SIDA MALI | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Université de Ouagadougou | Espace Confiance, Côte d'Ivoire | Espoir Vie-Togo - ONG | Laboratoire BIOLIM, Université de Lomé;COMPLETED;INTERVENTIONAL;False;2018-03-08;2017-11-20;2021-06-30;34048794;DERIVED;"Laurent C, Dembele Keita B, Yaya I, Le Guicher G, Sagaon-Teyssier L, Agboyibor MK, Coulibaly A, Traore I, Malan JB, De Baetselier I, Eubanks A, Riegel L, Rojas Castro D, Faye-Kette H, Kone A, Diande S, Dagnra CA, Serrano L, Diallo F, Mensah E, Dah TTE, Anoma C, Vuylsteke B, Spire B; CohMSM-PrEP Study Group. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study. Lancet HIV. 2021 Jul;8(7):e420-e428. doi: 10.1016/S2352-3018(21)00005-9. Epub 2021 May 25."
NCT01620957;Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma;Institut National de la Santé Et de la Recherche Médicale, France;University Hospital, Toulouse | Association des Traumatisés du Crane et de la Face, Paris, France;COMPLETED;OBSERVATIONAL;False;2012-06-15;2012-07-10;2017-07;;;
NCT00339157;Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2006-06-20;2006-06;2008-07;21173013;DERIVED;"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011 May;70(5):747-54. doi: 10.1136/ard.2010.134254. Epub 2010 Dec 20."
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;21256688;BACKGROUND;"Dejardin O, Berchi C, Mignon A, Pornet C, Guillaume E, Guittet L, Bouvier V, Sailly M, Salinas A, Christophe V, Launoy G. [Social inequalities in health from observational studies to intervention: can the patient navigator reduce social inequalities in cancer patients?]. Rev Epidemiol Sante Publique. 2011 Feb;59(1):45-51. doi: 10.1016/j.respe.2010.10.008. Epub 2011 Jan 21. French."
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;29909873;DERIVED;"De Mil R, Guillaume E, Guittet L, Dejardin O, Bouvier V, Pornet C, Christophe V, Notari A, Delattre-Massy H, De Seze C, Peng J, Launoy G, Berchi C. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial. Value Health. 2018 Jun;21(6):685-691. doi: 10.1016/j.jval.2017.09.020. Epub 2017 Nov 10."
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;28823681;DERIVED;"Guillaume E, Dejardin O, Bouvier V, De Mil R, Berchi C, Pornet C, Christophe V, Notari A, Delattre Massy H, De Seze C, Peng J, Guittet L, Launoy G. Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial. Prev Med. 2017 Oct;103:76-83. doi: 10.1016/j.ypmed.2017.08.012. Epub 2017 Aug 16."
NCT01348308;Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2011-05-05;2011-09;2016-03;32040959;DERIVED;"Levy Y, Lelievre JD, Assoumou L, Aznar E, Pulido F, Tambussi G, Crespo M, Meybeck A, Molina JM, Delaugerre C, Izopet J, Peytavin G, Cardon F, Diallo A, Lancar R, Beniguel L, Costagliola D. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial. Ann Intern Med. 2020 Mar 3;172(5):297-305. doi: 10.7326/M19-2133. Epub 2020 Feb 11."
NCT01696708;Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-10-01;2012-12-06;2015-11;25568297;DERIVED;"Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, Mochel F. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015 Feb 3;84(5):490-5. doi: 10.1212/WNL.0000000000001214. Epub 2015 Jan 7."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;32970730;DERIVED;"Iwuji C, Chimukuche RS, Zuma T, Plazy M, Larmarange J, Orne-Gliemann J, Siedner M, Shahmanesh M, Seeley J. Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa. PLoS One. 2020 Sep 24;15(9):e0239513. doi: 10.1371/journal.pone.0239513. eCollection 2020."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;31637821;DERIVED;"Larmarange J, Diallo MH, McGrath N, Iwuji C, Plazy M, Thiebaut R, Tanser F, Barnighausen T, Orne-Gliemann J, Pillay D, Dabis F; ANRS 12249 TasP Study Group. Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. J Int AIDS Soc. 2019 Oct;22(10):e25402. doi: 10.1002/jia2.25402."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30412926;DERIVED;"Perriat D, Plazy M, Gumede D, Boyer S, Pillay D, Dabis F, Seeley J, Orne-Gliemann J; ANRS 12249 TasP Study Group. ""If you are here at the clinic, you do not know how many people need help in the community"": Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat. PLoS One. 2018 Nov 9;13(11):e0202473. doi: 10.1371/journal.pone.0202473. eCollection 2018."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30321314;DERIVED;"Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Porter K, Pillay D. Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. Clin Infect Dis. 2019 Jul 2;69(2):207-214. doi: 10.1093/cid/ciy881."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30027600;DERIVED;"Larmarange J, Diallo MH, McGrath N, Iwuji C, Plazy M, Thiebaut R, Tanser F, Barnighausen T, Pillay D, Dabis F, Orne-Gliemann J; ANRS 12249 TasP Study Group. The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa). J Int AIDS Soc. 2018 Jul;21 Suppl 4(Suppl Suppl 4):e25128. doi: 10.1002/jia2.25128."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29890048;DERIVED;"Iwuji C, McGrath N, Calmy A, Dabis F, Pillay D, Newell ML, Baisley K, Porter K. Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. J Int AIDS Soc. 2018 Jun;21(6):e25112. doi: 10.1002/jia2.25112."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29199100;DERIVED;"Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, Okesola N, Makowa T, Dreyer J, Herbst K, McGrath N, Barnighausen T, Boyer S, De Oliveira T, Rekacewicz C, Bazin B, Newell ML, Pillay D, Dabis F; ANRS 12249 TasP Study Group. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018 Mar;5(3):e116-e125. doi: 10.1016/S2352-3018(17)30205-9. Epub 2017 Nov 30."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;28329393;DERIVED;"Collier D, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clin Infect Dis. 2017 Apr 15;64(8):1006-1016. doi: 10.1093/cid/cix015."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;27504637;DERIVED;"Iwuji CC, Orne-Gliemann J, Larmarange J, Okesola N, Tanser F, Thiebaut R, Rekacewicz C, Newell ML, Dabis F; ANRS 12249 TasP trial group. Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Med. 2016 Aug 9;13(8):e1002107. doi: 10.1371/journal.pmed.1002107. eCollection 2016 Aug."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;25880823;DERIVED;"Orne-Gliemann J, Larmarange J, Boyer S, Iwuji C, McGrath N, Barnighausen T, Zuma T, Dray-Spira R, Spire B, Rochat T, Lert F, Imrie J; ANRS 12249 TasP Group. Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health. 2015 Mar 1;15:209. doi: 10.1186/s12889-015-1344-y."
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;23880306;DERIVED;"Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, Imrie J, Barnighausen T, Rekacewicz C, Bazin B, Newell ML, Dabis F; ANRS 12249 TasP Study Group. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013 Jul 23;14:230. doi: 10.1186/1745-6215-14-230."
NCT01874808;From Movement Preparation to Gait Execution in ALS;Institut National de la Santé Et de la Recherche Médicale, France;Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement;COMPLETED;OBSERVATIONAL;False;2013-06-11;2013-06-21;2015-12-21;;;
NCT02126384;Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-30;2014-11-18;2016-04-05;;;
NCT03150290;Brown Adipose Tissue in ALS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-05-12;2017-10-26;2019-04-01;;;
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;21602695;BACKGROUND;"Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):290-6. doi: 10.1097/QAI.0b013e318221c56a."
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;22814853;BACKGROUND;"Van de Perre P, Rubbo PA, Viljoen J, Nagot N, Tylleskar T, Lepage P, Vendrell JP, Tuaillon E. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1. Sci Transl Med. 2012 Jul 18;4(143):143sr3. doi: 10.1126/scitranslmed.3003327."
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;26603917;BACKGROUND;"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Erratum In: Lancet. 2019 Jun 22;393(10190):2492."
NCT00465790;Research of Biomarkers in Parkinson Disease;Institut National de la Santé Et de la Recherche Médicale, France;European Union;COMPLETED;OBSERVATIONAL;False;2007-04-25;2007-10;2012-06;;;
NCT00122603;Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb | GlaxoSmithKline | Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-07-22;2005-12;2007-08;19420019;DERIVED;"Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vezinet F, Aboulker JP, Yeni P; ANRS 127 Study Group. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6."
NCT02314208;Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-11;2015-01;2018-01-01;;;
NCT00121121;Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-21;2004-07;2005-12;17712402;DERIVED;"Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guerin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725."
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15037514;RESULT;"Ahmad S, Fowler LJ, Whitton PS. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol. 2004 May;142(1):136-42. doi: 10.1038/sj.bjp.0705737. Epub 2004 Mar 22."
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15777732;RESULT;"Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. 2005 Feb;63(2-3):141-9. doi: 10.1016/j.eplepsyres.2005.02.002."
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;12914551;RESULT;"Aymard G, Berlin I, de Brettes B, Diquet B. Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. Fundam Clin Pharmacol. 2003 Aug;17(4):473-81. doi: 10.1046/j.1472-8206.2003.00152.x."
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15249613;RESULT;"Biraben A, Semah F, Ribeiro MJ, Douaud G, Remy P, Depaulis A. PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy. Neurology. 2004 Jul 13;63(1):73-7. doi: 10.1212/01.wnl.0000132840.40838.13."
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;2271377;RESULT;"Blin O, Masson G, Azulay JP, Fondarai J, Serratrice G. Apomorphine-induced blinking and yawning in healthy volunteers. Br J Clin Pharmacol. 1990 Nov;30(5):769-73. doi: 10.1111/j.1365-2125.1990.tb03848.x."
NCT02071784;Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-02-26;2014-07-08;2016-10-24;;;
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26709605;BACKGROUND;"Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016 May;17(5):358-67. doi: 10.1111/hiv.12348. Epub 2015 Dec 28."
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23766338;BACKGROUND;"Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group. Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial. Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12."
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23559464;BACKGROUND;"Andre-Schmutz I, Dal-Cortivo L, Six E, Kaltenbach S, Cocchiarella F, Le Chenadec J, Cagnard N, Cordier AG, Benachi A, Mandelbrot L, Azria E, Bouallag N, Luce S, Ternaux B, Reimann C, Revy P, Radford-Weiss I, Leschi C, Recchia A, Mavilio F, Cavazzana M, Blanche S. Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination. J Infect Dis. 2013 Jul 15;208(2):235-43. doi: 10.1093/infdis/jit149. Epub 2013 Apr 4."
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26854809;BACKGROUND;"Hleyhel M, Goujon S, Delteil C, Vasiljevic A, Luzi S, Stephan JL, Reliquet V, Jannier S, Tubiana R, Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J, Blanche S; ANRS French Perinatal Cohort Study Group. Risk of cancer in children exposed to didanosine in utero. AIDS. 2016 May 15;30(8):1245-56. doi: 10.1097/QAD.0000000000001051."
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26197844;BACKGROUND;"Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, Matheron S, Khuong MA, Garrait V, Reliquet V, Devidas A, Berrebi A, Allisy C, Elleau C, Arvieux C, Rouzioux C, Warszawski J, Blanche S; ANRS-EPF Study Group. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015 Dec 1;61(11):1715-25. doi: 10.1093/cid/civ578. Epub 2015 Jul 21."
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22160145;BACKGROUND;"Valantin MA, Lambert-Niclot S, Flandre P, Morand-Joubert L, Cabie A, Meynard JL, Ponscarme D, Ajana F, Slama L, Curjol A, Cuzin L, Schneider L, Taburet AM, Marcelin AG, Katlama C; MONOI ANRS 136 Study Group. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother. 2012 Mar;67(3):691-5. doi: 10.1093/jac/dkr504. Epub 2011 Dec 7."
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22848481;BACKGROUND;"Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One. 2012;7(7):e41390. doi: 10.1371/journal.pone.0041390. Epub 2012 Jul 25."
NCT02992184;PoC-HCV Genedrive Viral Detection Assay Validation Study;ANRS, Emerging Infectious Diseases;EPISTEM;COMPLETED;OBSERVATIONAL;False;2016-12-14;2016-09;2016-12;29615488;DERIVED;"Llibre A, Shimakawa Y, Mottez E, Ainsworth S, Buivan TP, Firth R, Harrison E, Rosenberg AR, Meritet JF, Fontanet A, Castan P, Madejon A, Laverick M, Glass A, Viana R, Pol S, McClure CP, Irving WL, Miele G, Albert ML, Duffy D. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut. 2018 Nov;67(11):2017-2024. doi: 10.1136/gutjnl-2017-315783. Epub 2018 Apr 3."
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;25556540;DERIVED;"Sultanik P, Mallet V, Lagaye S, Casrouge A, Dorival C, Barthe Y, Fontaine H, Hezode C, Mottez E, Bronowicki JP, Carrat F, Theodorou I, Abel L, Gayat E, Fontanet A, Pol S, Albert ML; ANRS CO20-CUPIC. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. Liver Int. 2015 Jul;35(7):1833-44. doi: 10.1111/liv.12759. Epub 2015 Jan 23."
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;24704719;DERIVED;"Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014 Jul;147(1):132-142.e4. doi: 10.1053/j.gastro.2014.03.051. Epub 2014 Apr 3."
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;23669289;DERIVED;"Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourliere M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Metivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013 Sep;59(3):434-41. doi: 10.1016/j.jhep.2013.04.035. Epub 2013 May 10."
NCT02212379;Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;True;2014-08-08;2015-01;2018-04;;;
NCT03652090;Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis;Institut National de la Santé Et de la Recherche Médicale, France;ABCF2;COMPLETED;OBSERVATIONAL;False;2018-08-29;2010-09-01;2016-03-03;;;
NCT00196664;Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-20;2005-10;2009-02;;;
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;32026446;DERIVED;"Sonneville R, Mazighi M, Bresson D, Crassard I, Crozier S, de Montmollin E, Degos V, Faugeras F, Gayat E, Josse L, Lamy C, Magalhaes E, Maldjian A, Ruckly S, Servan J, Vassel P, Vigue B, Timsit JF, Woimant F; SPICE investigators. Outcomes of Acute Stroke Patients Requiring Mechanical Ventilation: Study Protocol for the SPICE Multicenter Prospective Observational Study. Neurocrit Care. 2020 Apr;32(2):624-629. doi: 10.1007/s12028-019-00907-0."
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;30968368;DERIVED;"Garay OU, Nishimwe ML, Bousmah MA, Janah A, Girard PM, Chene G, Moinot L, Sagaon-Teyssier L, Meynard JL, Spire B, Boyer S. Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM). Pharmacoecon Open. 2019 Dec;3(4):505-515. doi: 10.1007/s41669-019-0130-7."
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;29767684;DERIVED;"Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L. Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382."
NCT02469350;Serious Game for Parkinson's Disease Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-11;2015-06;2017-10-04;29636105;DERIVED;"Nuic D, Vinti M, Karachi C, Foulon P, Van Hamme A, Welter ML. The feasibility and positive effects of a customised videogame rehabilitation programme for freezing of gait and falls in Parkinson's disease patients: a pilot study. J Neuroeng Rehabil. 2018 Apr 10;15(1):31. doi: 10.1186/s12984-018-0375-x."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25077537;RESULT;"Paques M, Miloudi C, Kulcsar C, Leseigneur A, Chaumette C, Koch E. High-resolution imaging of gunn's dots. Retina. 2015 Jan;35(1):120-4. doi: 10.1097/IAE.0000000000000269."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26344727;RESULT;"Audo I, Gocho K, Rossant F, Mohand-Said S, Loquin K, Bloch I, Sahel JA, Paques M. Functional and high-resolution retinal imaging monitoring photoreceptor damage in acute macular neuroretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):855-64. doi: 10.1007/s00417-015-3136-6. Epub 2015 Sep 7."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25997175;RESULT;"Paques M, Brolly A, Benesty J, Lerme N, Koch E, Rossant F, Bloch I, Girmens JF. Venous Nicking Without Arteriovenous Contact: The Role of the Arteriolar Microenvironment in Arteriovenous Nickings. JAMA Ophthalmol. 2015 Aug;133(8):947-50. doi: 10.1001/jamaophthalmol.2015.1132."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26523388;RESULT;"Miloudi C, Rossant F, Bloch I, Chaumette C, Leseigneur A, Sahel JA, Meimon S, Mrejen S, Paques M. The Negative Cone Mosaic: A New Manifestation of the Optical Stiles-Crawford Effect in Normal Eyes. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7043-50. doi: 10.1167/iovs.15-17022."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;23620431;RESULT;"Gocho K, Sarda V, Falah S, Sahel JA, Sennlaub F, Benchaboune M, Ullern M, Paques M. Adaptive optics imaging of geographic atrophy. Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3673-80. doi: 10.1167/iovs.12-10672."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24406779;RESULT;"Koch E, Rosenbaum D, Brolly A, Sahel JA, Chaumet-Riffaud P, Girerd X, Rossant F, Paques M. Morphometric analysis of small arteries in the human retina using adaptive optics imaging: relationship with blood pressure and focal vascular changes. J Hypertens. 2014 Apr;32(4):890-8. doi: 10.1097/HJH.0000000000000095."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24576889;RESULT;"Errera MH, Coisy S, Fardeau C, Sahel JA, Kallel S, Westcott M, Bodaghi B, Paques M. Retinal vasculitis imaging by adaptive optics. Ophthalmology. 2014 Jun;121(6):1311-2.e2. doi: 10.1016/j.ophtha.2013.12.036. Epub 2014 Feb 25. No abstract available."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24337723;RESULT;"Faure C, Gocho K, Le Mer Y, Sahel JA, Paques M, Audo I. Functional and high resolution retinal imaging assessment in a case of ocular siderosis. Doc Ophthalmol. 2014 Feb;128(1):69-75. doi: 10.1007/s10633-013-9421-y. Epub 2013 Dec 13."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;29369084;RESULT;"Bottin C, Grieve K, Rossant F, Pedinielli A, Mrejen S, Paques M. DIRECTIONAL VARIABILITY OF FUNDUS REFLECTANCE IN ACUTE MACULAR NEURORETINOPATHY: EVIDENCE FOR A CONTRIBUTION OF THE STILES-CRAWFORD EFFECT. Retin Cases Brief Rep. 2018 Fall;12 Suppl 1:S19-S24. doi: 10.1097/ICB.0000000000000701."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25284764;RESULT;"Jacob J, Paques M, Krivosic V, Dupas B, Couturier A, Kulcsar C, Tadayoni R, Massin P, Gaudric A. Meaning of visualizing retinal cone mosaic on adaptive optics images. Am J Ophthalmol. 2015 Jan;159(1):118-23.e1. doi: 10.1016/j.ajo.2014.09.043. Epub 2014 Oct 2."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27065002;RESULT;"Rosenbaum D, Mattina A, Koch E, Rossant F, Gallo A, Kachenoura N, Paques M, Redheuil A, Girerd X. Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics. J Hypertens. 2016 Jun;34(6):1115-22. doi: 10.1097/HJH.0000000000000894."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27009576;RESULT;"Rosenbaum D, Kachenoura N, Koch E, Paques M, Cluzel P, Redheuil A, Girerd X. Relationships between retinal arteriole anatomy and aortic geometry and function and peripheral resistance in hypertensives. Hypertens Res. 2016 Jul;39(7):536-42. doi: 10.1038/hr.2016.26. Epub 2016 Mar 24."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;28900746;RESULT;"Faure C, Paques M, Audo I. Electrophysiological features and multimodal imaging in ritonavir-related maculopathy. Doc Ophthalmol. 2017 Dec;135(3):241-248. doi: 10.1007/s10633-017-9612-z. Epub 2017 Sep 12."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30947025;RESULT;"Boileve A, Jozwiak M, Malka D, Boige V, Le Roy F, Paques M, Ducreux M. Vision loss after chemotherapy: an irinotecan-induced retinopathy. Eur J Cancer. 2019 May;112:80-82. doi: 10.1016/j.ejca.2019.02.015. Epub 2019 Apr 1. No abstract available."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30010022;RESULT;"Paques M, Meimon S, Rossant F, Rosenbaum D, Mrejen S, Sennlaub F, Grieve K. Adaptive optics ophthalmoscopy: Application to age-related macular degeneration and vascular diseases. Prog Retin Eye Res. 2018 Sep;66:1-16. doi: 10.1016/j.preteyeres.2018.07.001. Epub 2018 Jul 17."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31568064;RESULT;"Sodi A, Germain DP, Bacherini D, Finocchio L, Pacini B, Marziali E, Lenzetti C, Tanini I, Koraichi F, Coriat C, Nencini P, Olivotto I, Virgili G, Rizzo S, Paques M. IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. Retina. 2020 Aug;40(8):1623-1629. doi: 10.1097/IAE.0000000000002648."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31573376;RESULT;"Errera MH, Laguarrigue M, Rossant F, Koch E, Chaumette C, Fardeau C, Westcott M, Sahel JA, Bodaghi B, Benesty J, Paques M. High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study. Ocul Immunol Inflamm. 2020 Nov 16;28(8):1171-1180. doi: 10.1080/09273948.2019.1646773. Epub 2019 Oct 1."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31922497;RESULT;"Paques M, Rossant F, Finocchio L, Grieve K, Sahel JA, Pedinielli A, Mrejen S. ATTENUATION OUTER RETINAL BANDS ON OPTICAL COHERENCE TOMOGRAPHY FOLLOWING MACULAR EDEMA: A Possible Manifestation of Photoreceptor Misalignment. Retina. 2020 Nov;40(11):2232-2239. doi: 10.1097/IAE.0000000000002738."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31972545;RESULT;"Gallo A, Chaigneau E, Jublanc C, Rosenbaum D, Mattina A, Paques M, Rossant F, Girerd X, Leban M, Bruckert E. IGF-1 is an independent predictor of retinal arterioles remodeling in subjects with uncontrolled acromegaly. Eur J Endocrinol. 2020 Mar;182(3):375-383. doi: 10.1530/EJE-19-0390."
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26418443;DERIVED;"Jacob J, Krivosic V, Paques M, Tadayoni R, Gaudric A. CONE DENSITY LOSS ON ADAPTIVE OPTICS IN EARLY MACULAR TELANGIECTASIA TYPE 2. Retina. 2016 Mar;36(3):545-51. doi: 10.1097/IAE.0000000000000737."
NCT00122538;Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-22;2006-02;2009-05;23719348;DERIVED;"Bouazza N, Treluyer JM, Msellati P, Van de Perre P, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Hirt D, Urien S. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients. AIDS. 2013 Mar 13;27(5):761-8. doi: 10.1097/QAD.0b013e32835caad1."
NCT00122538;Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-22;2006-02;2009-05;21857286;DERIVED;"Barro M, Some J, Foulongne V, Diasso Y, Zoure E, Hien H, Francois R, Michel S, Drabo A, Tamboura H, Ouiminga A, Diagbouga S, Hien A, Yameogo S, Van De Perre P, Nacro B, Msellati P. Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname. J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S44-9. doi: 10.1097/QAI.0b013e31821fd64f."
NCT00122538;Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-22;2006-02;2009-05;20516271;DERIVED;"Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Treluyer JM, Msellati P, Urien S. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? Antimicrob Agents Chemother. 2010 Aug;54(8):3280-6. doi: 10.1128/AAC.00306-10. Epub 2010 Jun 1."
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;30096071;DERIVED;"Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963."
NCT04824638;BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2021-04-01;2021-03-08;2023-12-02;;;
NCT02113943;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-15;2014-04;2014-06;;;
NCT00299143;Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2006-03-06;2005-06;2010-06;;;
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;26603917;BACKGROUND;"Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Marechal V, Neveu D, Engebretsen IMS, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskar T, Van de Perre P; ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet. 2016 Feb 6;387(10018):566-573. doi: 10.1016/S0140-6736(15)00984-8. Epub 2015 Nov 19. Erratum In: Lancet. 2019 Jun 22;393(10190):2492."
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;33872801;BACKGROUND;"Mennecier A, Kankasa C, Fao P, Moles JP, Eymard-Duvernay S, Mwiya M, Kania D, Chunda-Liyoka C, Sakana L, Rutagwera D, Tassembedo S, Wilfred-Tonga MM, Mosqueira B, Tylleskar T, Nagot N, Van de Perre P; ANRS 12397 Study group. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso. Contemp Clin Trials. 2021 Jun;105:106402. doi: 10.1016/j.cct.2021.106402. Epub 2021 Apr 17."
NCT01605890;Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients;ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;True;2012-05-25;2012-07;2015-12;29590335;DERIVED;"Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G; France REcherche Nord&Sud Sida-Hiv Hepatites (ANRS) 159 HIV-2 Trial Study Group. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis. 2018 Sep 28;67(8):1161-1167. doi: 10.1093/cid/ciy245."
NCT00391638;Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Roche Pharma AG;COMPLETED;INTERVENTIONAL;False;2006-10-24;2007-01;2012-10;;;
NCT02323308;Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-12-23;2010-12;2014-06;;;
NCT02384967;Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-03-10;2015-03;2016-10;29905808;DERIVED;"Le MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193."
NCT00988767;Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-10-02;2001-02;2004-10;15382173;BACKGROUND;"Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004 Oct;40(4):874-82. doi: 10.1002/hep.20408."
NCT00988767;Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-10-02;2001-02;2004-10;16310901;RESULT;"Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine. 2006 May 22;24(21):4482-9. doi: 10.1016/j.vaccine.2005.08.013. Epub 2005 Aug 18."
NCT00988767;Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-10-02;2001-02;2004-10;20090916;DERIVED;"Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS One. 2010 Jan 18;5(1):e8761. doi: 10.1371/journal.pone.0008761."
NCT00323804;Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Rennes University Hospital;COMPLETED;INTERVENTIONAL;False;2006-05-10;2006-05;2013-03;;;
NCT04849767;National Survey About Trajectory and Life Conditions of HIV Trans People in France;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2021-04-19;2020-10-01;2023-12-31;34916316;DERIVED;"Mora M, Rincon G, Bourrelly M, Maradan G, Freire Maresca A, Michard F, Rouveix E, Pannetier J, Leriche D, Alain T, Yazdanpanah Y, Michels D, Spire B. Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV). BMJ Open. 2021 Dec 16;11(12):e052691. doi: 10.1136/bmjopen-2021-052691."
NCT03047967;Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-02-09;2017-11-10;2019-02-09;;;
NCT00120367;Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2005-07-18;2005-04;2007-12;21738597;DERIVED;"Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y; ANRS 125 Trial Team. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One. 2011;6(6):e20967. doi: 10.1371/journal.pone.0020967. Epub 2011 Jun 30."
NCT01038401;Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2009-12-24;2008-09;2010-05;;;
NCT04484740;Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue;Institut National de la Santé Et de la Recherche Médicale, France;Medical University of Vienna;COMPLETED;INTERVENTIONAL;False;2020-07-24;2021-01-29;2023-05-27;;;
NCT03078439;EPIPAGE2 Cohort Study Follow up at Five and a Half Years;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-13;2016-09-02;2018-01-08;;;
NCT00148863;Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C;French National Agency for Research on AIDS and Viral Hepatitis;InterMune | Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-08;2004-06;2007-08;23190183;DERIVED;"Couzigou P, Perusat S, Bourliere M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chene G; ANRS HC16 GAMMATRI Trial Group. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI). J Gastroenterol Hepatol. 2013 Feb;28(2):329-34. doi: 10.1111/jgh.12060."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;15634731;BACKGROUND;"Hummel F, Celnik P, Giraux P, Floel A, Wu WH, Gerloff C, Cohen LG. Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke. Brain. 2005 Mar;128(Pt 3):490-9. doi: 10.1093/brain/awh369. Epub 2005 Jan 5."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;20161639;BACKGROUND;"Madhavan S, Stinear JW. Focal and bi-directional modulation of lower limb motor cortex using anodal transcranial direct current stimulation. Brain Stimul. 2010 Jan;3(1):42. doi: 10.1016/j.brs.2009.06.005."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;22085959;BACKGROUND;"Nitsche MA, Paulus W. Transcranial direct current stimulation--update 2011. Restor Neurol Neurosci. 2011;29(6):463-92. doi: 10.3233/RNN-2011-0618."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;16002441;BACKGROUND;"Nitsche MA, Seeber A, Frommann K, Klein CC, Rochford C, Nitsche MS, Fricke K, Liebetanz D, Lang N, Antal A, Paulus W, Tergau F. Modulating parameters of excitability during and after transcranial direct current stimulation of the human motor cortex. J Physiol. 2005 Oct 1;568(Pt 1):291-303. doi: 10.1113/jphysiol.2005.092429. Epub 2005 Jul 7."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;11723286;BACKGROUND;"Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. Neurology. 2001 Nov 27;57(10):1899-901. doi: 10.1212/wnl.57.10.1899."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;10990547;BACKGROUND;"Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3(Pt 3):633-9. doi: 10.1111/j.1469-7793.2000.t01-1-00633.x."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;19805746;BACKGROUND;"Roche N, Lackmy A, Achache V, Bussel B, Katz R. Impact of transcranial direct current stimulation on spinal network excitability in humans. J Physiol. 2009 Dec 1;587(Pt 23):5653-64. doi: 10.1113/jphysiol.2009.177550. Epub 2009 Oct 5."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;15272049;BACKGROUND;"Sharshar T, Hopkinson NS, Jonville S, Prigent H, Carlier R, Dayer MJ, Swallow EB, Lofaso F, Moxham J, Polkey MI. Demonstration of a second rapidly conducting cortico-diaphragmatic pathway in humans. J Physiol. 2004 Nov 1;560(Pt 3):897-908. doi: 10.1113/jphysiol.2004.061150. Epub 2004 Jul 22."
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;8756819;BACKGROUND;"Similowski T, Catala M, Rancurel G, Derenne JP. Impairment of central motor conduction to the diaphragm in stroke. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):436-41. doi: 10.1164/ajrccm.154.2.8756819."
NCT00302822;Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-03-15;2006-04;2009-12;;;
NCT00196625;Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-20;2000-11;2002-02;15456093;RESULT;"Raguin G, Chene G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM; Puzzle 1 Study Group. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther. 2004 Aug;9(4):615-25."
NCT00196625;Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-20;2000-11;2002-02;15060509;RESULT;"Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chene G, Clavel F, Girard PM. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004 Apr;75(4):310-23. doi: 10.1016/j.clpt.2003.12.013."
NCT01188525;Pharmacokinetic Study to Characterize Individual Metabolic Profile;Institut National de la Santé Et de la Recherche Médicale, France;Nuclear Energy Commission (CEA);COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2011-07;;;
NCT00670839;Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST);ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2008-05-02;2008-05;2013-02;26257021;DERIVED;"Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F; ANRS HB04 B-BOOST study group. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015 Nov;15(11):1283-91. doi: 10.1016/S1473-3099(15)00220-0. Epub 2015 Aug 6."
NCT00158522;Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-02;2007-12;16434426;BACKGROUND;"Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut. 2006 Aug;55(8):1183-7. doi: 10.1136/gut.2005.078147. Epub 2006 Jan 24."
NCT00158522;Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-02;2007-12;15977225;BACKGROUND;"El Gaafary MM, Rekacewicz C, Abdel-Rahman AG, Allam MF, El Hosseiny M, Hamid MA, Colombani F, Sultan Y, El-Aidy S, Fontanet A, Mohamed MK. Surveillance of acute hepatitis C in Cairo, Egypt. J Med Virol. 2005 Aug;76(4):520-5. doi: 10.1002/jmv.20392."
NCT00196586;Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-20;2003-04;2006-11;;;
NCT04808986;Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-03-22;2021-05-10;2021-10-12;;;
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34352834;DERIVED;"Dah TTE, Yaya I, Mensah E, Coulibaly A, Kouame JM, Traore I, Mora M, Palvadeau P, Anoma C, Keita BD, Spire B, Laurent C; CohMSM Study Group. Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa. AIDS. 2021 Nov 1;35(13):2201-2210. doi: 10.1097/QAD.0000000000003046."
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34022820;DERIVED;"Dah TTE, Yaya I, Sagaon-Teyssier L, Coulibaly A, Kouame MJ, Agboyibor MK, Maiga K, Traore I, Mora M, Palvadeau P, Rojas-Castro D, Diallo F, Mensah E, Anoma C, Keita BD, Spire B, Laurent C; CohMSM Study Group. Adherence to quarterly HIV prevention services and its impact on HIV incidence in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France). BMC Public Health. 2021 May 22;21(1):972. doi: 10.1186/s12889-021-10994-4."
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;33753460;DERIVED;"Yaya I, Diallo F, Kouame MJ, Agboyibor MK, Traore I, Coulibaly A, Maiga K, Mora M, Palvadeau P, Dah ETT, Mensah E, Anoma C, Dembele Keita B, Spire B, Laurent C; CohMSM Study Group. Decrease in incidence of sexually transmitted infections symptoms in men who have sex with men enrolled in a quarterly HIV prevention and care programme in West Africa (CohMSM ANRS 12324-Expertise France). Sex Transm Infect. 2022 Mar;98(2):85-94. doi: 10.1136/sextrans-2020-054755. Epub 2021 Mar 22."
NCT01207986;Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2010-09-23;2011-02;2014-08;;;
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25086286;BACKGROUND;"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45-57. doi: 10.1016/j.jhep.2014.07.027. Epub 2014 Jul 30."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23172780;BACKGROUND;"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22828983;BACKGROUND;"Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic). 2012 Sep-Oct;11(5):311-20. doi: 10.1177/1545109712453939. Epub 2012 Jul 24."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20041309;BACKGROUND;"Clatts MC, Colon-Lopez V, Giang LM, Goldsamt LA. Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. J Urban Health. 2010 Mar;87(2):278-291. doi: 10.1007/s11524-009-9417-9."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22098550;BACKGROUND;"Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, Trinh HN; International Group for Liver Health in Viet Nam. Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action. J Gastroenterol Hepatol. 2012 Feb;27(2):238-47. doi: 10.1111/j.1440-1746.2011.06974.x."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20196807;BACKGROUND;"Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, Wrobel VJ, Srishord M, Younossi ZM. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat. 2011 Jan;18(1):70-6. doi: 10.1111/j.1365-2893.2010.01278.x."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;19839502;BACKGROUND;"Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, Akkarathamrongsin S, Theamboonlers A, Poovorawan Y. High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol. 2009 Jun-Sep;27(2-3):153-60."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20572071;BACKGROUND;"Tanimoto T, Nguyen HC, Ishizaki A, Chung PT, Hoang TT, Nguyen VT, Kageyama S, Oka S, Pham VT, Ichimura H. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. J Med Virol. 2010 Aug;82(8):1355-63. doi: 10.1002/jmv.21787."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23675659;BACKGROUND;"Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013 May 16;368(20):1907-17. doi: 10.1056/NEJMra1213651."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25920094;BACKGROUND;"Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015 Apr;62(1 Suppl):S87-99. doi: 10.1016/j.jhep.2015.02.006."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23553643;BACKGROUND;"Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013 Nov;58(5):1598-609. doi: 10.1002/hep.26431. Epub 2013 Aug 26."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23728143;BACKGROUND;"Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013 Oct;57(7):1014-20. doi: 10.1093/cid/cit377. Epub 2013 May 31."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27667367;BACKGROUND;"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22. No abstract available."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25245939;BACKGROUND;"Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6. doi: 10.1016/j.drugpo.2014.08.014. Epub 2014 Aug 30."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27178119;BACKGROUND;"Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27227200;BACKGROUND;"Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. Geneva: World Health Organization; 2016 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK362924/"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27148964;BACKGROUND;"Nguyen Truong T, Laureillard D, Lacombe K, Duong Thi H, Pham Thi Hanh P, Truong Thi Xuan L, Chu Thi N, Luong Que A, Vu Hai V, Nagot N, Tuaillon E, Dominguez S, Lemoine M. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262). PLoS One. 2016 May 5;11(5):e0153744. doi: 10.1371/journal.pone.0153744. eCollection 2016."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23884064;BACKGROUND;"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013 Aug;57 Suppl 2(Suppl 2):S39-45. doi: 10.1093/cid/cit296. Erratum In: Clin Infect Dis. 2014 Apr;58(8):1203."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27427455;BACKGROUND;"Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stover H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016 Sep 17;388(10050):1228-48. doi: 10.1016/S0140-6736(16)30856-X. Epub 2016 Jul 14."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22564041;BACKGROUND;"Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012 Nov;107(11):1984-95. doi: 10.1111/j.1360-0443.2012.03932.x. Epub 2012 Jul 12."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;26298331;BACKGROUND;"Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015 Oct;26(10):911-21. doi: 10.1016/j.drugpo.2015.07.004. Epub 2015 Jul 26."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27349488;BACKGROUND;"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24."
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;33208326;DERIVED;"Rapoud D, Quillet C, Pham Minh K, Vu Hai V, Nguyen Thanh B, Nham Thi Tuyet T, Tran Thi H, Moles JP, Vallo R, Michel L, Feelemyer J, Weiss L, Lemoine M, Vickerman P, Fraser H, Duong Thi H, Khuat Thi Hai O, Des Jarlais D, Nagot N, Laureillard D; DRIVE-C Study Group. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C). BMJ Open. 2020 Nov 18;10(11):e039234. doi: 10.1136/bmjopen-2020-039234."
NCT04684758;HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2020-12-28;2021-04-14;2022-06-30;;;
NCT00121758;AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;Aventis Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2005-07-21;2004-09;2007-12;23759749;DERIVED;"Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelievre JD, Chene G, Thiebaut R, Levy Y; ANRS Vaccine Network/Vaccine Research Institute. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS. 2013 Jun 1;27(9):1421-31. doi: 10.1097/QAD.0b013e32835f5b60."
NCT00121758;AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;Aventis Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2005-07-21;2004-09;2007-12;20625264;DERIVED;"Salmon-Ceron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelievre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Levy Y, Launay O; ANRS VAC18 trial group. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS. 2010 Sep 10;24(14):2211-23. doi: 10.1097/QAD.0b013e32833ce566."
NCT02527096;A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol);ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2015-08-18;2015-09-17;2017-03;;;
NCT00158457;Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-06;2006-12;;;
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16193476;RESULT;"Klebe S, Durr A, Rentschler A, Hahn-Barma V, Abele M, Bouslam N, Schols L, Jedynak P, Forlani S, Denis E, Dussert C, Agid Y, Bauer P, Globas C, Wullner U, Brice A, Riess O, Stevanin G. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol. 2005 Nov;58(5):720-9. doi: 10.1002/ana.20628."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15313841;RESULT;"Stevanin G, Hahn V, Lohmann E, Bouslam N, Gouttard M, Soumphonphakdy C, Welter ML, Ollagnon-Roman E, Lemainque A, Ruberg M, Brice A, Durr A. Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14. Arch Neurol. 2004 Aug;61(8):1242-8. doi: 10.1001/archneur.61.8.1242."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15365159;RESULT;"Stevanin G, Durr A, Dussert C, Penet C, Brice A. Mutations in the FGF14 gene are not a major cause of spinocerebellar ataxia in Caucasians. Neurology. 2004 Sep 14;63(5):936. doi: 10.1212/01.wnl.0000137020.30604.1e. No abstract available."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16501573;RESULT;"Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D, Mock AF, Evidente VG, Fee DB, Muller U, Durr A, Brice A, Papazian DM, Pulst SM. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet. 2006 Apr;38(4):447-51. doi: 10.1038/ng1758. Epub 2006 Feb 26."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16055926;RESULT;"Depienne C, Tallaksen C, Lephay JY, Bricka B, Poea-Guyon S, Fontaine B, Labauge P, Brice A, Durr A. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet. 2006 Mar;43(3):259-65. doi: 10.1136/jmg.2005.035311. Epub 2005 Jul 31."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17098887;RESULT;"Depienne C, Fedirko E, Forlani S, Cazeneuve C, Ribai P, Feki I, Tallaksen C, Nguyen K, Stankoff B, Ruberg M, Stevanin G, Durr A, Brice A. Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. J Med Genet. 2007 Apr;44(4):281-4. doi: 10.1136/jmg.2006.046425. Epub 2006 Nov 10."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17597328;RESULT;"Depienne C, Fedirko E, Faucheux JM, Forlani S, Bricka B, Goizet C, Lesourd S, Stevanin G, Ruberg M, Durr A, Brice A. A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP. Neurogenetics. 2007 Aug;8(3):231-3. doi: 10.1007/s10048-007-0090-4. Epub 2007 Jun 28."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17605047;RESULT;"Hanein S, Durr A, Ribai P, Forlani S, Leutenegger AL, Nelson I, Babron MC, Elleuch N, Depienne C, Charon C, Brice A, Stevanin G. A novel locus for autosomal dominant ""uncomplicated"" hereditary spastic paraplegia maps to chromosome 8p21.1-q13.3. Hum Genet. 2007 Nov;122(3-4):261-73. doi: 10.1007/s00439-007-0396-1. Epub 2007 Jun 28."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17957230;RESULT;"Ribai P, Depienne C, Fedirko E, Jothy AC, Viveweger C, Hahn-Barma V, Brice A, Durr A. Mental deficiency in three families with SPG4 spastic paraplegia. Eur J Hum Genet. 2008 Jan;16(1):97-104. doi: 10.1038/sj.ejhg.5201922. Epub 2007 Oct 24."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18378516;RESULT;"du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, Guyant-Marechal L, Forlani S, Jauffret C, Vandenberghe N, N'guyen K, Le Ber I, Devos D, Vincitorio CM, Manto MU, Tison F, Hannequin D, Ruberg M, Brice A, Durr A. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain. 2008 May;131(Pt 5):1352-61. doi: 10.1093/brain/awn059. Epub 2008 Mar 31."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18853458;RESULT;"Goizet C, Boukhris A, Mundwiller E, Tallaksen C, Forlani S, Toutain A, Carriere N, Paquis V, Depienne C, Durr A, Stevanin G, Brice A. Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10. Hum Mutat. 2009 Feb;30(2):E376-85. doi: 10.1002/humu.20920."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;24780882;DERIVED;"Tezenas du Montcel S, Durr A, Rakowicz M, Nanetti L, Charles P, Sulek A, Mariotti C, Rola R, Schols L, Bauer P, Dufaure-Gare I, Jacobi H, Forlani S, Schmitz-Hubsch T, Filla A, Timmann D, van de Warrenburg BP, Marelli C, Kang JS, Giunti P, Cook A, Baliko L, Melegh B, Boesch S, Szymanski S, Berciano J, Infante J, Buerk K, Masciullo M, Di Fabio R, Depondt C, Ratka S, Stevanin G, Klockgether T, Brice A, Golmard JL. Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. J Med Genet. 2014 Jul;51(7):479-86. doi: 10.1136/jmedgenet-2013-102200. Epub 2014 Apr 29. Erratum In: J Med Genet. 2014 Sep;51(9):613. Bela, Melegh [corrected to Melegh, Bela]."
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;22491195;DERIVED;"Tezenas du Montcel S, Charles P, Goizet C, Marelli C, Ribai P, Vincitorio C, Anheim M, Guyant-Marechal L, Le Bayon A, Vandenberghe N, Tchikviladze M, Devos D, Le Ber I, N'Guyen K, Cazeneuve C, Tallaksen C, Brice A, Durr A. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia. Arch Neurol. 2012 Apr;69(4):500-8. doi: 10.1001/archneurol.2011.2713."
NCT01579435;Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-18;2012-04;2013-04;;;
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;32558469;DERIVED;"Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, Samreth S, Nguyen BD, Borand L, Domergue A, Rapoud D, Natukunda N, Thai S, Juchet S, Eholie SP, Lawn SD, Domoua SK, Anglaret X, Laureillard D; STATIS ANRS 12290 Trial Team. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med. 2020 Jun 18;382(25):2397-2410. doi: 10.1056/NEJMoa1910708."
NCT01713335;Proteasis Evaluation in COPD;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-24;2012-10-18;2017-04;;;
NCT02073630;Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-02;2016-08;;;
NCT05040048;Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Innovative Medicines Initiative | Institut d'Investigacions Biomèdiques August Pi i Sunyer | ICM Co. Ltd. | University Hospital, Bonn | Karolinska Institutet;COMPLETED;OBSERVATIONAL;False;2021-09-10;2015-09-04;2018-02;;;
NCT03446430;Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2018-02-26;2018-06-21;2018-12-04;;;
NCT01094899;Abnormal Structure and Bone Density in Diabetes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-29;2010-03-10;2014-07-10;;;
NCT03193099;Decoding Presymptomatic White Matter Changes in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;University College, London;COMPLETED;INTERVENTIONAL;False;2017-06-20;2017-07-11;2019-12-30;;;
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;33743621;BACKGROUND;"Vessiere A, Font H, Gabillard D, Adonis-Koffi L, Borand L, Chabala C, Khosa C, Mavale S, Moh R, Mulenga V, Mwanga-Amumpere J, Taguebue JV, Eang MT, Delacourt C, Seddon JA, Lounnas M, Godreuil S, Wobudeya E, Bonnet M, Marcy O. Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial. BMC Pediatr. 2021 Mar 20;21(1):136. doi: 10.1186/s12887-021-02576-5."
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;36395782;DERIVED;"Marcy O, Wobudeya E, Font H, Vessiere A, Chabala C, Khosa C, Taguebue JV, Moh R, Mwanga-Amumpaire J, Lounnas M, Mulenga V, Mavale S, Chilundo J, Rego D, Nduna B, Shankalala P, Chirwa U, De Lauzanne A, Dim B, Tiogouo Ngouana E, Folquet Amorrissani M, Cisse L, Amon Tanoh Dick F, Komena EA, Kwedi Nolna S, Businge G, Natukunda N, Cumbe S, Mbekeka P, Kim A, Kheang C, Pol S, Maleche-Obimbo E, Seddon JA, Mao TE, Graham SM, Delacourt C, Borand L, Bonnet M; TB-Speed Pneumonia Study Group. Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial. Lancet Infect Dis. 2023 Mar;23(3):341-351. doi: 10.1016/S1473-3099(22)00668-5. Epub 2022 Nov 14."
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;32853411;DERIVED;"Kay AW, Gonzalez Fernandez L, Takwoingi Y, Eisenhut M, Detjen AK, Steingart KR, Mandalakas AM. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD013359. doi: 10.1002/14651858.CD013359.pub2."
NCT00148824;Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.;French National Agency for Research on AIDS and Viral Hepatitis;Wyeth is now a wholly owned subsidiary of Pfizer;COMPLETED;INTERVENTIONAL;False;2005-09-08;2003-02;2006-01;20210645;DERIVED;"Rabian C, Tschope I, Lesprit P, Katlama C, Molina JM, Meynard JL, Delfraissy JF, Chene G, Levy Y; ANRS 114 Pneumovac Study Group. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. Clin Infect Dis. 2010 Apr 15;50(8):1174-83. doi: 10.1086/651418."
NCT00901524;ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV;ANRS, Emerging Infectious Diseases;Roche Pharma AG;COMPLETED;INTERVENTIONAL;False;2009-05-13;2009-06;2012-06;24905490;DERIVED;"Laird ME, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A, Pawlotsky JM, Hezode C, Rosa I, Renard P, Mohamed MK, Bonnard P, Izopet J, Mallet V, Pol S, Albert ML, Fontanet A. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. J Hepatol. 2014 Oct;61(4):770-6. doi: 10.1016/j.jhep.2014.05.040. Epub 2014 Jun 4."
NCT00870649;Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-03-27;2009-02;2012-12;30532268;DERIVED;"Riveau G, Schacht AM, Dompnier JP, Deplanque D, Seck M, Waucquier N, Senghor S, Delcroix-Genete D, Hermann E, Idris-Khodja N, Levy-Marchal C, Capron M, Capron A. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children. PLoS Negl Trop Dis. 2018 Dec 7;12(12):e0006968. doi: 10.1371/journal.pntd.0006968. eCollection 2018 Dec."
NCT01207349;Type 2 Diabetes Secondary Prevention;Institut National de la Santé Et de la Recherche Médicale, France;Groupe Hospitalier Sud Réunion;COMPLETED;OBSERVATIONAL;False;2010-09-22;2002-08;2004-12;22030240;DERIVED;"Debussche X, Rollot O, Le Pommelet C, Fianu A, Le Moullec N, Regnier C, Boyer MC, Cogne M, Bakiri F, Schwager JC, Favier F. Quarterly individual outpatients lifestyle counseling after initial inpatients education on type 2 diabetes: the REDIA Prev-2 randomized controlled trial in Reunion Island. Diabetes Metab. 2012 Feb;38(1):46-53. doi: 10.1016/j.diabet.2011.07.002. Epub 2011 Oct 24."
NCT01531036;3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-02-10;2010-12;2012-11;20505064;BACKGROUND;"Athanasiou A, Tardivon A, Tanter M, Sigal-Zafrani B, Bercoff J, Deffieux T, Gennisson JL, Fink M, Neuenschwander S. Breast lesions: quantitative elastography with supersonic shear imaging--preliminary results. Radiology. 2010 Jul;256(1):297-303. doi: 10.1148/radiol.10090385. Epub 2010 May 26."
NCT00651066;Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-02;2010-06;2012-09;24465443;DERIVED;"Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TT, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014 Jan 22;9(1):e84866. doi: 10.1371/journal.pone.0084866. eCollection 2014."
NCT02081066;Identification of CETP as a Marker of Atherosclerosis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-07;2014-09-25;2020-09;;;
NCT01164436;Cohort of HIV Associated Lymphomas;ANRS, Emerging Infectious Diseases;Dr Yassine Taoufik Dr Houria Chavez Hôpital Bicêtre CIB Paris Sud France | Dr Guislaine Garcelain Hôpital Pitié Slapétrière Paris France | University Hospital, Grenoble | Dr Irène Joab Hôpital Paul Brousse Villejuif France | Dr Alex Duval Fondation Jean Dausset CEPH | Hopital Antoine Beclere;COMPLETED;OBSERVATIONAL;False;2010-07-16;2008-06;2017-06;;;
NCT01038999;Accelerated Aging, HIV Infection, Antiretroviral Therapies;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;OBSERVATIONAL;False;2009-12-24;2009-04;2012-03;23285253;DERIVED;"Perrin S, Cremer J, Faucher O, Reynes J, Dellamonica P, Micallef J, Solas C, Lacarelle B, Stretti C, Kaspi E, Robaglia-Schlupp A, Nicolino-Brunet C, Tamalet C, Levy N, Poizot-Martin I, Cau P, Roll P. HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 ""aging"" study. PLoS One. 2012;7(12):e53035. doi: 10.1371/journal.pone.0053035. Epub 2012 Dec 28. Erratum In: PLoS One. 2013;8(8). doi:10.1371/annotation/f02cdfd3-b271-46fd-a78f-5a030f0b416d. Tamalet, Corine Nicolino-Brunet Catherine [corrected to Nicolino-Brunet, Corinne]; [ corrected to Tamalet, Catherine]."
NCT01038999;Accelerated Aging, HIV Infection, Antiretroviral Therapies;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;OBSERVATIONAL;False;2009-12-24;2009-04;2012-03;22829920;DERIVED;"Perrin S, Cremer J, Roll P, Faucher O, Menard A, Reynes J, Dellamonica P, Naqvi A, Micallef J, Jouve E, Tamalet C, Solas C, Pissier C, Arnoux I, Nicolino-Brunet C, Espinosa L, Levy N, Kaspi E, Robaglia-Schlupp A, Poizot-Martin I, Cau P. HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 ""Aging"" study. PLoS One. 2012;7(7):e41129. doi: 10.1371/journal.pone.0041129. Epub 2012 Jul 19."
NCT00604149;Cardiac AResT And GENEtic;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2008-01-30;2008-01;2014-01;;;
NCT01569399;Efficacity of rTMS in Alcohol Dependance;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-03;2011-02-11;2016-08;;;
NCT01917175;Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-08-06;1997-06;2018-09;;;
NCT01592175;Magnetoencephalography (MEG), Attention and Conscience;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-05-07;2012-03-08;2013-07-02;;;
NCT01271842;Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2011-01-07;2010-10;;22948576;DERIVED;"Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J; REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep;142(3):583-592. doi: 10.1378/chest.11-2196."
NCT00265642;Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C;ANRS, Emerging Infectious Diseases;Sanofi;COMPLETED;INTERVENTIONAL;False;2005-12-15;2006-10;2013-11;;;
NCT01008813;Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac);French National Agency for Research on AIDS and Viral Hepatitis;GlaxoSmithKline;COMPLETED;INTERVENTIONAL;False;2009-11-06;2009-10;2010-12;;;
NCT00158470;Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-09;2007-05;;;
NCT04265742;Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture;Institut National de la Santé Et de la Recherche Médicale, France;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2020-02-12;2019-02-08;2022-02-04;;;
NCT04631224;Longitudinal Analysis of Oral Communication in Friedreich's Ataxia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-11-17;2015-02;2017-02;;;
NCT01493934;Development of a Fast Measurement Technique of Insulin Resistance in Human;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-16;2010-04;2013-03;;;
NCT02978924;Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-01;2017-01-17;2017-11-28;;;
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;17624825;BACKGROUND;"Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis. 2007 Aug 15;196 Suppl 1:S46-51. doi: 10.1086/518658."
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;24759827;DERIVED;"Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis. 2014 Aug 1;59(3):435-45. doi: 10.1093/cid/ciu283. Epub 2014 Apr 23."
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;24096631;DERIVED;"Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M, Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295 - CIPRA KH001) Study Team. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS. 2013 Oct 23;27(16):2577-86. doi: 10.1097/01.aids.0000432456.14099.c7."
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;24608960;DERIVED;"Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, Taburet AM. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS One. 2014 Mar 7;9(3):e90350. doi: 10.1371/journal.pone.0090350. eCollection 2014."
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;23237982;DERIVED;"Borand L, Laureillard D, Madec Y, Chou M, Pheng P, Marcy O, Sok T, Goldfeld AE, Taburet AM, Blanc FX; CAMELIA ANRS 1295-CIPRA KH001 Study Team. Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg. Antivir Ther. 2013;18(3):419-23. doi: 10.3851/IMP2483. Epub 2012 Dec 12."
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;22010913;DERIVED;"Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE; CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1471-81. doi: 10.1056/NEJMoa1013911."
NCT04392388;Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-05-18;2020-05-01;2023-04-11;;;
NCT00928187;Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé);ANRS, Emerging Infectious Diseases;Gilead Sciences | Janssen Pharmaceutica;COMPLETED;INTERVENTIONAL;True;2009-06-25;2009-11;2015-12;31273686;DERIVED;"Boyer S, Nishimwe ML, Sagaon-Teyssier L, March L, Koulla-Shiro S, Bousmah MQ, Toby R, Mpoudi-Etame MP, Ngom Gueye NF, Sawadogo A, Kouanfack C, Ciaffi L, Spire B, Delaporte E; 2-Lady Group. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa. Pharmacoecon Open. 2020 Mar;4(1):45-60. doi: 10.1007/s41669-019-0157-9."
NCT00640887;Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-02;2010-10;26482301;DERIVED;"Hennig S, Naiker S, Reddy T, Egan D, Kellerman T, Wiesner L, Owen A, McIlleron H, Pym A. Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. Antimicrob Agents Chemother. 2015 Oct 19;60(1):617-20. doi: 10.1128/AAC.01195-15. Print 2016 Jan."
NCT00640887;Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-02;2010-10;25406657;DERIVED;"Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, McIlleron H, Lienhardt C, Pym A. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol. 2014 Nov 19;15:61. doi: 10.1186/2050-6511-15-61."
NCT01952587;X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-30;2013-11;2015-06;;;
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;28753830;DERIVED;"Yiou R, Hamidou L, Birebent B, Bitari D, Le Corvoisier P, Contremoulins I, Rodriguez AM, Augustin D, Roudot-Thoraval F, de la Taille A, Rouard H. Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial. Eur Urol Focus. 2017 Dec;3(6):643-645. doi: 10.1016/j.euf.2017.06.009. Epub 2017 Jun 24."
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;25974235;DERIVED;"Khera M, Albersen M, Mulhall JP. Mesenchymal stem cell therapy for the treatment of erectile dysfunction. J Sex Med. 2015 May;12(5):1105-6. doi: 10.1111/jsm.12871. No abstract available."
NCT02833961;Diffusion Spectroscopy in Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-07-14;2016-07-28;2019-10-25;;;
NCT02453061;A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2015-05-25;2015-06-29;2019-12-03;31381524;DERIVED;"Rodrigues FB, Ferreira JJ, Wild EJ. Huntington's Disease Clinical Trials Corner: June 2019. J Huntingtons Dis. 2019;8(3):363-371. doi: 10.3233/JHD-199003."
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;20403152;RESULT;"Orne-Gliemann J, Tchendjou PT, Miric M, Gadgil M, Butsashvili M, Eboko F, Perez-Then E, Darak S, Kulkarni S, Kamkamidze G, Balestre E, du Lou AD, Dabis F. Couple-oriented prenatal HIV counseling for HIV primary prevention: an acceptability study. BMC Public Health. 2010 Apr 19;10:197. doi: 10.1186/1471-2458-10-197."
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;21857289;RESULT;"Tchendjou PT, Koki PN, Eboko F, Malateste K, Essounga AN, Amassana D, Mossus T, Tejiokem M, Boisier P, Orne-Gliemann J. Factors associated with history of HIV testing among pregnant women and their partners in Cameroon: baseline data from a Behavioral Intervention Trial (ANRS 12127 Prenahtest). J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S9-15. doi: 10.1097/QAI.0b013e31821ec6e2."
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;34329355;DERIVED;"Kengne-Nde C, Tejiokem MC, Orne-Gliemann J, Melingui B, Koki Ndombo P, Essounga NA, Bissek AC, Cauchemez S, Tchendjou PT. Couple oriented counselling improves male partner involvement in sexual and reproductive health of a couple: Evidence from the ANRS PRENAHTEST randomized trial. PLoS One. 2021 Jul 30;16(7):e0255330. doi: 10.1371/journal.pone.0255330. eCollection 2021."
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;29178852;DERIVED;"Tiendrebeogo T, Plazy M, Darak S, Miric M, Perez-Then E, Butsashvili M, Tchendjou P, Dabis F, Orne-Gliemann J. Couples HIV counselling and couple relationships in India, Georgia and the Dominican Republic. BMC Public Health. 2017 Nov 25;17(1):901. doi: 10.1186/s12889-017-4901-8."
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;23343912;DERIVED;"Orne-Gliemann J, Balestre E, Tchendjou P, Miric M, Darak S, Butsashvili M, Perez-Then E, Eboko F, Plazy M, Kulkarni S, Desgrees du Lou A, Dabis F; Prenahtest ANRS 12127 Study Group. Increasing HIV testing among male partners. AIDS. 2013 Apr 24;27(7):1167-77. doi: 10.1097/QAD.0b013e32835f1d8c."
NCT00301561;Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2006-03-13;2006-05;2010-10;35248123;DERIVED;"Sandie AB, Molinari N, Wanjoya A, Kouanfack C, Laurent C, Tchatchueng-Mbougua JB. Non-inferiority test for a continuous variable with a flexible margin in an active controlled trial: an application to the ""Stratall ANRS 12110 / ESTHER"" trial. Trials. 2022 Mar 5;23(1):202. doi: 10.1186/s13063-022-06118-x."
NCT00301561;Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2006-03-13;2006-05;2010-10;21831714;DERIVED;"Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, Carrieri MP, Mben JM, Dontsop M, Kaze S, Molinari N, Bourgeois A, Mpoudi-Ngole E, Spire B, Koulla-Shiro S, Delaporte E; Stratall ANRS 12110/ESTHER study group. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis. 2011 Nov;11(11):825-33. doi: 10.1016/S1473-3099(11)70168-2. Epub 2011 Aug 8."
NCT01167283;Effect of Electrostimulation in Chronic Obstructive Pulmonary Disease (COPD);Institut National de la Santé Et de la Recherche Médicale, France;Centre Hospitalier Régional Universitaire Montpellier;COMPLETED;INTERVENTIONAL;False;2010-07-22;2006-07;2010-04;;;
NCT02150993;First-Line Treatment for HIV-2;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-05-30;2016-01-26;2019-05-15;;;
NCT01075061;"Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET "" MOMIC """;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-02-24;2010-02;2011-07;;;
NCT02014883;Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2013-12-18;2013-12-04;2019-07-04;26536893;DERIVED;"Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, Heron B, Roubertie A, Kaphan E, Valabregue R, Rinaldi D, Vuillaumier S, Schiffmann R, Ottolenghi C, Hogrel JY, Servais L, Roze E. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016 May;87(5):550-3. doi: 10.1136/jnnp-2015-311475. Epub 2015 Nov 3."
NCT00158483;Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-05;2005-10;16455895;BACKGROUND;"Legoff J, Bouhlal H, Gresenguet G, Weiss H, Khonde N, Hocini H, Desire N, Si-Mohamed A, de Dieu Longo J, Chemin C, Frost E, Pepin J, Malkin JE, Mayaud P, Belec L. Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol. 2006 Feb;44(2):423-32. doi: 10.1128/JCM.44.2.423-432.2006."
NCT00158483;Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-05;2005-10;18385443;BACKGROUND;"LeGoff J, Mayaud P, Gresenguet G, Weiss HA, Nzambi K, Frost E, Pepin J, Belec L; ANRS 12-12 Study Group. Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. J Clin Microbiol. 2008 Jun;46(6):1914-8. doi: 10.1128/JCM.02332-07. Epub 2008 Apr 2."
NCT00158483;Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-05;2005-10;19530940;DERIVED;"Mayaud P, Legoff J, Weiss HA, Gresenguet G, Nzambi K, Bouhlal H, Frost E, Pepin J, Malkin JE, Hayes RJ, Mabey DC, Belec L; ANRS 1212 Study Group. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis. 2009 Jul 15;200(2):216-26. doi: 10.1086/599991."
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;20413309;BACKGROUND;"Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord. 2010 Jun;20(6):414-21. doi: 10.1016/j.nmd.2010.03.014. Epub 2010 Apr 21. No abstract available."
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;24975859;BACKGROUND;"Lloyd TE, Mammen AL, Amato AA, Weiss MD, Needham M, Greenberg SA. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014 Jul 29;83(5):426-33. doi: 10.1212/WNL.0000000000000642. Epub 2014 Jun 27."
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;25435054;BACKGROUND;"Mentre F, Taburet AM, Guedj J, Anglaret X, Keita S, de Lamballerie X, Malvy D. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015 Feb;15(2):150-1. doi: 10.1016/S1473-3099(14)71047-3. Epub 2014 Nov 28. No abstract available."
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;27046271;RESULT;"Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wolfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Gunther S, de Lamballerie X, Keita S, Mentre F, Anglaret X, Malvy D; JIKI Study Group. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr."
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;28231247;DERIVED;"Nguyen TH, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentre F; JIKI study group. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb."
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;26930627;DERIVED;"Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Rene Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wolfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Gunther S, de Lamballerie X, Keita S, Mentre F, Anglaret X, Malvy D; JIKI Study Group. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum In: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D'Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066."
NCT02027233;Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-06;2014-01;2022-12-31;;;
NCT02093754;Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-21;2014-05;2016-03;;;
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27317796;RESULT;"Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A, Esterle L, Chas J, Poizot-Martin I, Dominguez S, Simon A, Morlat P, Neau D, Zucman D, Bouchaud O, Lascoux-Combe C, Bani-Sadr F, Alric L, Goujard C, Vittecoq D, Billaud E, Aumaitre H, Boue F, Valantin MA, Dabis F, Salmon D, Wittkop L. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. Clin Infect Dis. 2016 Sep 15;63(6):763-770. doi: 10.1093/cid/ciw379. Epub 2016 Jun 17."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27177169;RESULT;"Marcellin F, Protopopescu C, Poizot-Martin I, Miailhes P, Esterle L, Wittkop L, Spire B, Bocquier A, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group. Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1003-7. doi: 10.1097/MEG.0000000000000664."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27073179;RESULT;"Marcellin F, Lions C, Rosenthal E, Roux P, Sogni P, Wittkop L, Protopopescu C, Spire B, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group*. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort). Drug Alcohol Rev. 2017 Mar;36(2):227-238. doi: 10.1111/dar.12398. Epub 2016 Apr 13."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25778750;RESULT;"Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217. Epub 2015 Mar 16."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25015913;RESULT;"Marcellin F, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, Salmon-Ceron D, Spire B, Carrieri MP; HEPAVIH (ANRS CO13) Study Group. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. Clin Infect Dis. 2014 Oct 15;59(8):1190-2. doi: 10.1093/cid/ciu525. Epub 2014 Jul 11. No abstract available."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26528903;RESULT;"Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, Morlat P, Loko MA, Wittkop L, Dabis F; ANRS CO13HEPAVIH study group. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. J Clin Virol. 2015 Dec;73:32-35. doi: 10.1016/j.jcv.2015.10.010. Epub 2015 Oct 19."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26372388;RESULT;"ANRS CO13 HEPAVIH Cohort. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. AIDS. 2015 Sep 10;29(14):1821-30. doi: 10.1097/QAD.0000000000000787."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24166726;RESULT;"Roux P, Lions C, Cohen J, Winnock M, Salmon-Ceron D, Bani-Sadr F, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH Study Group. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther. 2014;19(2):171-8. doi: 10.3851/IMP2699. Epub 2013 Oct 28."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24580042;RESULT;"Marcellin F, Roux P, Winnock M, Lions C, Dabis F, Salmon-Ceron D, Loko MA, Spire B, Carrieri MP. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. Expert Rev Gastroenterol Hepatol. 2014 May;8(4):351-8. doi: 10.1586/17474124.2014.888949. Epub 2014 Mar 3."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23978720;RESULT;"Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol. 2014 Jan;60(1):46-53. doi: 10.1016/j.jhep.2013.08.014. Epub 2013 Aug 24."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24499953;RESULT;"Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, Duvivier C, Bouchaud O, Gervais A, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response. AIDS. 2014 May 15;28(8):1155-60. doi: 10.1097/QAD.0000000000000218."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23461846;RESULT;"Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, Morlat P, Marchou B, Dabis F, Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group. Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions. HIV Med. 2013 Aug;14(7):430-6. doi: 10.1111/hiv.12023. Epub 2013 Mar 5."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23421419;RESULT;"Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, Mora M, Loko MA, Dabis F, Dominguez S, Roux P, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort). Addiction. 2013 Jul;108(7):1250-8. doi: 10.1111/add.12149. Epub 2013 Mar 21."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22285372;RESULT;"Trimoulet P, Merchadou L, Winnock M, Loko MA, Fleury H, Salmon D, Dabis F, Neau D; ANRS CO 13 HEPAVIH Study Group. Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples? J Virol Methods. 2012 Apr;181(1):131-3. doi: 10.1016/j.jviromet.2012.01.006. Epub 2012 Jan 20."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22781224;RESULT;"Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G; ANRS CO-13 HEPAVIH Study Group. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS. 2012 Nov 13;26(17):2193-9. doi: 10.1097/QAD.0b013e32835763a4."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22409788;RESULT;"Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22173166;RESULT;"Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol. 2012 Apr;56(4):862-8. doi: 10.1016/j.jhep.2011.11.009. Epub 2011 Dec 13."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21819472;RESULT;"Roux P, Fugon L, Winnock M, Salmon-Ceron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO-13-HEPAVIH Study Group. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction. 2012 Jan;107(1):152-9. doi: 10.1111/j.1360-0443.2011.03608.x. Epub 2011 Oct 12."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23052829;RESULT;"Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22535683;RESULT;"Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B; HEPAVIH Study Group. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology. 2012 Nov;56(5):2010. doi: 10.1002/hep.25813. No abstract available."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21888878;RESULT;"Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M. Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH. J Hepatol. 2012 Mar;56(3):745-7. doi: 10.1016/j.jhep.2011.08.005. Epub 2011 Aug 31. No abstract available."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23226258;RESULT;"Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, Trimoulet P, Dabis F, Salmon-Ceron D, Izopet J; ANRS CO13 HEPAVIH Study Group. HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289. Epub 2012 Nov 30."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21920402;RESULT;"Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Lascoux-Combe C, Garipuy D, Rosenthal E, Carrieri P, Dabis F, Salmon D. Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. Vaccine. 2011 Nov 3;29(47):8656-60. doi: 10.1016/j.vaccine.2011.08.125. Epub 2011 Sep 13."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21239121;RESULT;"Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH study group. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. Drug Alcohol Depend. 2011 Jul 1;116(1-3):228-32. doi: 10.1016/j.drugalcdep.2010.09.025. Epub 2011 Jan 15."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21692942;RESULT;"Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, Morlat P, Serfaty L, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepat. 2011 Jul;18(7):e307-14. doi: 10.1111/j.1365-2893.2010.01417.x. Epub 2011 Jan 11."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20969743;RESULT;"Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, Poizot-Martin I, Neau D, Bonnard P, Rosenthal E, Barange K, Morlat P, Lacombe K, Gervais A, Rouges F, See AB, Lascoux-Combe C, Vittecoq D, Goujard C, Duvivier C, Spire B, Izopet J, Sogni P, Serfaty L, Benhamou Y, Bani-Sadr F, Dabis F; ANRS CO 13 HEPAVIH Study Group. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis. 2010 Oct 22;10:303. doi: 10.1186/1471-2334-10-303."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20876416;RESULT;"Carrieri MP, Cohen J, Winnock M, Salmon D. Chocolate intake, depression, and clinical progression in HIV-HCV coinfected patients: still more questions than answers. Arch Intern Med. 2010 Sep 27;170(17):1607; author reply 1608-9. doi: 10.1001/archinternmed.2010.330. No abstract available."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20493576;RESULT;"Cales P, Halfon P, Batisse D, Carrat F, Perre P, Penaranda G, Guyader D, d'Alteroche L, Fouchard-Hubert I, Michelet C, Veillon P, Lambert J, Weiss L, Salmon D, Cacoub P. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol. 2010 Aug;53(2):238-44. doi: 10.1016/j.jhep.2010.03.007. Epub 2010 Apr 18."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28942916;RESULT;"Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, Zucman D, Raffi F, Rosenthal E, Poizot-Martin I, Salmon-Ceron D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol. 2017 Dec;67(6):1157-1167. doi: 10.1016/j.jhep.2017.08.005. Epub 2017 Sep 21."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28780609;RESULT;"Yaya I, Roux P, Marcellin F, Salmon-Ceron D, Carrieri MP. Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort). Dig Dis Sci. 2017 Oct;62(10):2943-2944. doi: 10.1007/s10620-017-4703-y. Epub 2017 Aug 5. No abstract available."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28430385;RESULT;"Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, Boue F, Rey D, Piroth L, Dominguez S, Sogni P, Salmon-Ceron D, Spire B, Carrieri MP; ANRS CO13-HEPAVIH Study Group. Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort. Addiction. 2017 Sep;112(9):1669-1679. doi: 10.1111/add.13851. Epub 2017 Jun 6."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28418984;RESULT;"Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, Bouchaud O, Goujard C, Vittecoq D, Dabis F, Salmon-Ceron D, Spire B, Roux P, Carrieri MP; ANRS CO13-HEPAVIH Study Group. Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). Eur J Gastroenterol Hepatol. 2017 Jul;29(7):786-791. doi: 10.1097/MEG.0000000000000883."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28235612;RESULT;"Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boue F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D; ANRS CO13 HEPAVIH study group. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017 Jul;67(1):23-31. doi: 10.1016/j.jhep.2017.02.012. Epub 2017 Feb 22."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27339598;RESULT;"Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, Coulonges C, Carpentier W, Nalpas B, Heim MH, Poynard T, Cerny A, Pol S, Bochud PY, Dabis F, Theodorou I, Levy Y, Salmon D, Abel L, Dominguez S, Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group; Swiss Hepatitis C Cohort Study Group; French ANRS HC EP 26 Genoscan Study Group. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology. 2016 Nov;64(5):1462-1472. doi: 10.1002/hep.28695. Epub 2016 Jul 29."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;34212476;DERIVED;"Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, Esterle L, Gilbert C, Miailhes P, Zucman D, Valantin MA, Bregigeon-Ronot S, Morlat P, Billaud E, Piroth L, Naqvi A, Sogni P, Salmon D; ANRS CO13 HEPAVIH Cohort Study Group. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. HIV Med. 2021 Oct;22(9):791-804. doi: 10.1111/hiv.13127. Epub 2021 Jul 1."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;32798585;DERIVED;"Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Marc-Lacombe J, Esterle L, Dorival C, Bourliere M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. J Hepatol. 2021 Jan;74(1):37-47. doi: 10.1016/j.jhep.2020.08.008. Epub 2020 Aug 14."
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;30570526;DERIVED;"Poizot-Martin I, Rosenthal E, Gilbert C, Cano CE, Simon A, Lascoux-Combe C, Alric L, Gervais A, Neau D, Esterle L, Salmon D, Sogni P, Wittkop L; ANRS CO13 HEPAVIH Study Group. Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):461-466. doi: 10.1097/QAI.0000000000001940."
NCT04842851;Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle;Paris Cardiovascular Research Center (Inserm U970);Marie Lannelongue Hospital, Le Plessis Robinson, France | Clinique Pasteur Toulouse | Groupe Hospitalier Pitie-Salpetriere | Hopital Louis Pradel | University Hospital, Montpellier | European Georges Pompidou Hospital;COMPLETED;OBSERVATIONAL;False;2021-04-13;2004-01-01;2020-12-31;;;
NCT04409405;Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola);Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo | Institut de Recherche pour le Developpement;COMPLETED;OBSERVATIONAL;False;2020-06-01;2020-04-16;2021-10-18;;;
NCT00158405;Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-12;2006-12;16152755;BACKGROUND;"Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10(5):615-24. doi: 10.1177/135965350501000510."
NCT00158405;Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-12;2006-12;16782488;RESULT;"Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholie S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 trial group. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006 Jun 17;367(9527):1981-9. doi: 10.1016/S0140-6736(06)68887-9."
NCT00158405;Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-12;2006-12;18986246;RESULT;"Danel C, Moh R, Chaix ML, Gabillard D, Gnokoro J, Diby CJ, Toni T, Dohoun L, Rouzioux C, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 Trial Group. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis. 2009 Jan 1;199(1):66-76. doi: 10.1086/595298."
NCT02960698;Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-10;2016-10-14;2018-04-24;;;
NCT02931097;DBS of the MLR for Gait and Balance Disorders in PD Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-10-12;2016-10;2020-10;;;
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;27770695;DERIVED;"Carrieri P, Vilotitch A, Nordmann S, Lions C, Michel L, Mora M, Morel A, Maradan G, Spire B, Roux P; Methaville Study Group. Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial). Int J Drug Policy. 2017 Jan;39:86-91. doi: 10.1016/j.drugpo.2016.08.005. Epub 2016 Oct 19."
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;27048152;DERIVED;"Roux P, Lions C, Vilotitch A, Michel L, Mora M, Maradan G, Marcellin F, Spire B, Morel A, Carrieri PM; ANRS Methaville study group. Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study). Harm Reduct J. 2016 Apr 5;13:12. doi: 10.1186/s12954-016-0100-7."
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;25393311;DERIVED;"Carrieri PM, Michel L, Lions C, Cohen J, Vray M, Mora M, Marcellin F, Spire B, Morel A, Roux P; Methaville Study Group. Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS One. 2014 Nov 13;9(11):e112328. doi: 10.1371/journal.pone.0112328. eCollection 2014."
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;25209306;DERIVED;"Roux P, Lions C, Michel L, Mora M, Daulouede JP, Marcellin F, Spire B, Morel A, Carrieri PM; ANRS Methaville study group. Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions. Subst Abuse Treat Prev Policy. 2014 Sep 10;9:37. doi: 10.1186/1747-597X-9-37."
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;24268548;DERIVED;"Lions C, Carrieri MP, Michel L, Mora M, Marcellin F, Morel A, Spire B, Roux P; Methaville Study Group. Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial). Drug Alcohol Depend. 2014 Feb 1;135:1-8. doi: 10.1016/j.drugalcdep.2013.10.018. Epub 2013 Oct 31."
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;22741944;DERIVED;"Roux P, Michel L, Cohen J, Mora M, Morel A, Aubertin JF, Desenclos JC, Spire B, Carrieri PM; ANRS Methaville Study Group. Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial. BMC Public Health. 2012 Jun 28;12:488. doi: 10.1186/1471-2458-12-488."
NCT00421551;Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136;French National Agency for Research on AIDS and Viral Hepatitis;Tibotec Pharmaceutical Limited;COMPLETED;INTERVENTIONAL;False;2007-01-12;2007-03;2011-02;29767684;DERIVED;"Lambert-Niclot S, Grude M, Meynard JL, Marcelin AG, Valantin MA, Flandre P, Izopet J, Moinot L, Bouteloup V, Calvez V, Katlama C, Girard PM, Morand-Joubert L. Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. Clin Infect Dis. 2018 Nov 28;67(12):1883-1889. doi: 10.1093/cid/ciy382."
NCT00421551;Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136;French National Agency for Research on AIDS and Viral Hepatitis;Tibotec Pharmaceutical Limited;COMPLETED;INTERVENTIONAL;False;2007-01-12;2007-03;2011-02;22848481;DERIVED;"Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks. PLoS One. 2012;7(7):e41390. doi: 10.1371/journal.pone.0041390. Epub 2012 Jul 25."
NCT00421551;Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136;French National Agency for Research on AIDS and Viral Hepatitis;Tibotec Pharmaceutical Limited;COMPLETED;INTERVENTIONAL;False;2007-01-12;2007-03;2011-02;20802297;DERIVED;"Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010 Sep 24;24(15):2365-74. doi: 10.1097/QAD.0b013e32833dec20."
NCT00623051;Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-02-25;2008-01;2012-12;;;
NCT00116454;Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2005-06-30;2005-07;2013-08;;;
NCT03954054;Therapeutic Education for Harm Reduction in People With Alcohol Use Disorder;Institut National de la Santé Et de la Recherche Médicale, France;Regional Agency for Health PACA | SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD);COMPLETED;OBSERVATIONAL;False;2019-05-17;2019-10-28;2021-07-31;35012570;DERIVED;"Antwerpes S, Costa M, Coste M, Bureau M, Maradan G, Cutarella C, Leloutre J, Riccobono-Soulier O, Hedoire S, Frot E, Vernier F, Vassas-Goyard S, Barre T, Casanova D, Carrieri P. Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduct J. 2022 Jan 10;19(1):2. doi: 10.1186/s12954-021-00587-0."
NCT02976298;Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-29;2013-02;2015-01;;;
NCT02101398;Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-02;2014-10-02;2016-07;;;
NCT05472051;Health and Migration Trajectories of Housekeepers in Bamako;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2022-07-25;2022-02-28;2023-06-22;;;
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;35093007;DERIVED;"Moh DR, Ntakpe JB, Gabillard D, Yayo-Emieme AA, Badje A, Kouame GM, d'Aquin TT, Danel C, Anglaret X, Eholie SP. Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults. BMC Infect Dis. 2022 Jan 29;22(1):100. doi: 10.1186/s12879-022-07082-2."
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29297443;DERIVED;"Moh R, Badje A, N'takpe JB, Kouame GM, Gabillard D, Ouassa T, Ouattara E, Le Carrou J, Bohoussou F, Messou E, Eholie S, Anglaret X, Danel C. Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults. Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1237-1244. doi: 10.5588/ijtld.17.0016."
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29020361;DERIVED;"Kouame GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, Ntakpe JB, Emieme A, Maylin S, Chekaraou MA, Eholie SP, Zoulim F, Lacombe K, Anglaret X, Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. Clin Infect Dis. 2018 Jan 6;66(1):112-120. doi: 10.1093/cid/cix747."
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;26193126;DERIVED;"TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpe JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouame A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibe B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouame E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundze S, Hawerlander D, Ani A, Dembele F, Kone F, Guehi C, Kanga C, Koule S, Seri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoue G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semde C, Kouame A, Massumbuko JM, Chene G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholie SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20."
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;25330161;DERIVED;"Danel C, Kabran M, Inwoley A, Badje A, Herrmann JL, Moh R, Lecarrou J, Gabillard D, Ntakpe JB, Deschamps N, Ouattara E, Perronne C, Eholie S, Anglaret X. Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Cote d'Ivoire, West Africa. PLoS One. 2014 Oct 16;9(10):e107245. doi: 10.1371/journal.pone.0107245. eCollection 2014."
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;24985779;DERIVED;"Jean K, Gabillard D, Moh R, Danel C, Desgrees-du-Lou A, N'takpe JB, Le Carrou J, Badje A, Eholie S, Lert F, Anglaret X, Dray-Spira R. Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Cote d'Ivoire. J Int AIDS Soc. 2014 Jun 30;17(1):18977. doi: 10.7448/IAS.17.1.18977. eCollection 2014."
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;23639243;DERIVED;"Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. J Int AIDS Soc. 2013 Apr 30;16(1):18059. doi: 10.7448/IAS.16.1.18059."
NCT01693861;"""Cancersensor"" Chemotherapy";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-10;2015-02;;;
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;15557412;RESULT;"Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briancon S. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004 Nov 22;164(21):2335-42. doi: 10.1001/archinte.164.21.2335. Erratum In: Arch Intern Med. 2005 Feb 14;165(3):286."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;33738534;DERIVED;"Andreeva VA, Peneau S, Julia C, Shivappa N, Hebert JR, Wirth MD, Touvier M, Hercberg S, Galan P, Kesse-Guyot E. The inflammatory potential of the diet is prospectively associated with subjective hearing loss. Eur J Nutr. 2021 Oct;60(7):3669-3678. doi: 10.1007/s00394-021-02531-1. Epub 2021 Mar 18."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;31927670;DERIVED;"Lecuyer L, Dalle C, Micheau P, Petera M, Centeno D, Lyan B, Lagree M, Galan P, Hercberg S, Rossary A, Demidem A, Vasson MP, Partula V, Deschasaux M, Srour B, Latino-Martel P, Druesne-Pecollo N, Kesse-Guyot E, Durand S, Pujos-Guillot E, Manach C, Touvier M. Untargeted plasma metabolomic profiles associated with overall diet in women from the SU.VI.MAX cohort. Eur J Nutr. 2020 Dec;59(8):3425-3439. doi: 10.1007/s00394-020-02177-5. Epub 2020 Jan 11."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;31164347;DERIVED;"Lecuyer L, Dalle C, Lyan B, Demidem A, Rossary A, Vasson MP, Petera M, Lagree M, Ferreira T, Centeno D, Galan P, Hercberg S, Deschasaux M, Partula V, Srour B, Latino-Martel P, Kesse-Guyot E, Druesne-Pecollo N, Durand S, Pujos-Guillot E, Touvier M. Plasma Metabolomic Signatures Associated with Long-term Breast Cancer Risk in the SU.VI.MAX Prospective Cohort. Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1300-1307. doi: 10.1158/1055-9965.EPI-19-0154. Epub 2019 Jun 4."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;30517725;DERIVED;"Assmann KE, Adjibade M, Hercberg S, Galan P, Kesse-Guyot E. Unsaturated Fatty Acid Intakes During Midlife Are Positively Associated with Later Cognitive Function in Older Adults with Modulating Effects of Antioxidant Supplementation. J Nutr. 2018 Dec 1;148(12):1938-1945. doi: 10.1093/jn/nxy206."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;29649036;DERIVED;"Wiernik E, Lemogne C, Fezeu L, Arnault N, Hercberg S, Kesse-Guyot E, Galan P. Association Between Alexithymia and Risk of Incident Cardiovascular Diseases in the SUpplementation en VItamines et Mineraux AntioXydants (SU.VI.MAX) Cohort. Psychosom Med. 2018 Jun;80(5):460-467. doi: 10.1097/PSY.0000000000000592."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;29546305;DERIVED;"Assmann KE, Adjibade M, Shivappa N, Hebert JR, Wirth MD, Touvier M, Akbaraly T, Hercberg S, Galan P, Julia C, Kesse-Guyot E. The Inflammatory Potential of the Diet at Midlife Is Associated with Later Healthy Aging in French Adults. J Nutr. 2018 Mar 1;148(3):437-444. doi: 10.1093/jn/nxx061."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;28494135;DERIVED;"Ruhunuhewa I, Adjibade M, Andreeva VA, Galan P, Hercberg S, Assmann KE, Kesse-Guyot E. Prospective association between body mass index at midlife and healthy aging among French adults. Obesity (Silver Spring). 2017 Jul;25(7):1254-1262. doi: 10.1002/oby.21853. Epub 2017 May 11."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;28356432;DERIVED;"Adjibade M, Andreeva VA, Lemogne C, Touvier M, Shivappa N, Hebert JR, Wirth MD, Hercberg S, Galan P, Julia C, Assmann KE, Kesse-Guyot E. The Inflammatory Potential of the Diet Is Associated with Depressive Symptoms in Different Subgroups of the General Population. J Nutr. 2017 May;147(5):879-887. doi: 10.3945/jn.116.245167. Epub 2017 Mar 29."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;28033414;DERIVED;"Walker V, Perret-Guillaume C, Kesse-Guyot E, Agrinier N, Hercberg S, Galan P, Assmann KE, Briancon S, Rotonda C. Effect of Multimorbidity on Health-Related Quality of Life in Adults Aged 55 Years or Older: Results from the SU.VI.MAX 2 Cohort. PLoS One. 2016 Dec 29;11(12):e0169282. doi: 10.1371/journal.pone.0169282. eCollection 2016."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;27055851;DERIVED;"Kesse-Guyot E, Assmann KE, Andreeva VA, Touvier M, Neufcourt L, Shivappa N, Hebert JR, Wirth MD, Hercberg S, Galan P, Julia C. Long-term association between the dietary inflammatory index and cognitive functioning: findings from the SU.VI.MAX study. Eur J Nutr. 2017 Jun;56(4):1647-1655. doi: 10.1007/s00394-016-1211-3. Epub 2016 Apr 7."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;27000099;DERIVED;"Adriouch S, Julia C, Kesse-Guyot E, Mejean C, Ducrot P, Peneau S, Donnenfeld M, Deschasaux M, Menai M, Hercberg S, Touvier M, Fezeu LK. Prospective association between a dietary quality index based on a nutrient profiling system and cardiovascular disease risk. Eur J Prev Cardiol. 2016 Oct;23(15):1669-76. doi: 10.1177/2047487316640659. Epub 2016 Mar 21."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26962176;DERIVED;"Graffouillere L, Deschasaux M, Mariotti F, Neufcourt L, Shivappa N, Hebert JR, Wirth MD, Latino-Martel P, Hercberg S, Galan P, Julia C, Kesse-Guyot E, Touvier M. The Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study. J Nutr. 2016 Apr 1;146(4):785-791. doi: 10.3945/jn.115.225623. Epub 2016 Mar 9."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26864363;DERIVED;"Graffouillere L, Deschasaux M, Mariotti F, Neufcourt L, Shivappa N, Hebert JR, Wirth MD, Latino-Martel P, Hercberg S, Galan P, Julia C, Kesse-Guyot E, Touvier M. Prospective association between the Dietary Inflammatory Index and mortality: modulation by antioxidant supplementation in the SU.VI.MAX randomized controlled trial. Am J Clin Nutr. 2016 Mar;103(3):878-85. doi: 10.3945/ajcn.115.126243. Epub 2016 Feb 10."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26817718;DERIVED;"Deschasaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, Ezzedine K, Touvier M. Weight Status and Alcohol Intake Modify the Association between Vitamin D and Breast Cancer Risk. J Nutr. 2016 Mar;146(3):576-85. doi: 10.3945/jn.115.221481. Epub 2016 Jan 27."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26812508;DERIVED;"Kesse-Guyot E, Assmann KE, Andreeva VA, Ferry M, Hercberg S, Galan P; SU.VI.MAX 2 Research Group. Consumption of Dairy Products and Cognitive Functioning: Findings from the SU.VI.MAX 2 Study. J Nutr Health Aging. 2016 Feb;20(2):128-37. doi: 10.1007/s12603-015-0593-x."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26447153;DERIVED;"Deschasaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, Ezzedine K, Touvier M. Prospective associations between vitamin D status, vitamin D-related gene polymorphisms, and risk of tobacco-related cancers. Am J Clin Nutr. 2015 Nov;102(5):1207-15. doi: 10.3945/ajcn.115.110510. Epub 2015 Oct 7."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26409628;DERIVED;"Kesse-Guyot E, Lassale C, Assmann KE, Andreeva VA, Julia C, Blacher J, Fezeu L, Hercberg S, Galan P. Are different vascular risk scores calculated at midlife uniformly associated with subsequent poor cognitive performance? Atherosclerosis. 2015 Nov;243(1):286-92. doi: 10.1016/j.atherosclerosis.2015.09.023. Epub 2015 Sep 21."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26156743;DERIVED;"Donnenfeld M, Deschasaux M, Latino-Martel P, Diallo A, Galan P, Hercberg S, Ezzedine K, Touvier M. Prospective association between dietary folate intake and skin cancer risk: results from the Supplementation en Vitamines et Mineraux Antioxydants cohort. Am J Clin Nutr. 2015 Aug;102(2):471-8. doi: 10.3945/ajcn.115.109041. Epub 2015 Jul 8."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;25994566;DERIVED;"Chhim AS, Fassier P, Latino-Martel P, Druesne-Pecollo N, Zelek L, Duverger L, Hercberg S, Galan P, Deschasaux M, Touvier M. Prospective association between alcohol intake and hormone-dependent cancer risk: modulation by dietary fiber intake. Am J Clin Nutr. 2015 Jul;102(1):182-9. doi: 10.3945/ajcn.114.098418. Epub 2015 May 20."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;25651444;DERIVED;"Kesse-Guyot E, Andreeva VA, Touvier M, Jeandel C, Ferry M, Hercberg S, Galan P; SU.VI.MAX 2 Research Group. Overall and abdominal adiposity in midlife and subsequent cognitive function. J Nutr Health Aging. 2015 Feb;19(2):183-9. doi: 10.1007/s12603-014-0508-2."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24553693;DERIVED;"Deschasaux M, Pouchieu C, His M, Hercberg S, Latino-Martel P, Touvier M. Dietary total and insoluble fiber intakes are inversely associated with prostate cancer risk. J Nutr. 2014 Apr;144(4):504-10. doi: 10.3945/jn.113.189670. Epub 2014 Feb 19."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24527713;DERIVED;"Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, Fezeu LK, Latino-Martel P, Druesne-Pecollo N, Malvy D, Galan P, Hercberg S, Ezzedine K, Souberbielle JC. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab. 2014 Apr;99(4):1196-203. doi: 10.1210/jc.2013-3349. Epub 2014 Feb 14."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24089418;DERIVED;"Andreeva VA, Galan P, Arnaud J, Julia C, Hercberg S, Kesse-Guyot E. Midlife iron status is inversely associated with subsequent cognitive performance, particularly in perimenopausal women. J Nutr. 2013 Dec;143(12):1974-81. doi: 10.3945/jn.113.177089. Epub 2013 Oct 2."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24027184;DERIVED;"Julia C, Touvier M, Meunier N, Papet I, Galan P, Hercberg S, Kesse-Guyot E. Intakes of PUFAs were inversely associated with plasma C-reactive protein 12 years later in a middle-aged population with vitamin E intake as an effect modifier. J Nutr. 2013 Nov;143(11):1760-6. doi: 10.3945/jn.113.180943. Epub 2013 Sep 11."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;23284983;DERIVED;"Kesse-Guyot E, Andreeva VA, Jeandel C, Ferry M, Touvier M, Hercberg S, Galan P. Alcohol consumption in midlife and cognitive performance assessed 13 years later in the SU.VI.MAX 2 cohort. PLoS One. 2012;7(12):e52311. doi: 10.1371/journal.pone.0052311. Epub 2012 Dec 19."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;23283500;DERIVED;"Kesse-Guyot E, Andreeva VA, Lassale C, Ferry M, Jeandel C, Hercberg S, Galan P; SU.VI.MAX 2 Research Group. Mediterranean diet and cognitive function: a French study. Am J Clin Nutr. 2013 Feb;97(2):369-76. doi: 10.3945/ajcn.112.047993. Epub 2013 Jan 2."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;23082222;DERIVED;"Kesse-Guyot E, Charreire H, Andreeva VA, Touvier M, Hercberg S, Galan P, Oppert JM. Cross-sectional and longitudinal associations of different sedentary behaviors with cognitive performance in older adults. PLoS One. 2012;7(10):e47831. doi: 10.1371/journal.pone.0047831. Epub 2012 Oct 17."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;22633793;DERIVED;"Kesse-Guyot E, Ahluwalia N, Lassale C, Hercberg S, Fezeu L, Lairon D. Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a 6-year prospective study. Nutr Metab Cardiovasc Dis. 2013 Jul;23(7):677-83. doi: 10.1016/j.numecd.2012.02.005. Epub 2012 May 25."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;22378736;DERIVED;"Touvier M, Kesse-Guyot E, Andreeva VA, Fezeu L, Charnaux N, Sutton A, Druesne-Pecollo N, Hercberg S, Galan P, Zelek L, Latino-Martel P, Czernichow S. Modulation of the association between plasma intercellular adhesion molecule-1 and cancer risk by n-3 PUFA intake: a nested case-control study. Am J Clin Nutr. 2012 Apr;95(4):944-50. doi: 10.3945/ajcn.111.027805. Epub 2012 Feb 29."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;22158670;DERIVED;"Briancon S, Boini S, Bertrais S, Guillemin F, Galan P, Hercberg S. Long-term antioxidant supplementation has no effect on health-related quality of life: the randomized, double-blind, placebo-controlled, primary prevention SU.VI.MAX trial. Int J Epidemiol. 2011 Dec;40(6):1605-16. doi: 10.1093/ije/dyr161."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21955649;DERIVED;"Peneau S, Galan P, Jeandel C, Ferry M, Andreeva V, Hercberg S, Kesse-Guyot E; SU.VI.MAX 2 Research Group. Fruit and vegetable intake and cognitive function in the SU.VI.MAX 2 prospective study. Am J Clin Nutr. 2011 Nov;94(5):1295-303. doi: 10.3945/ajcn.111.014712. Epub 2011 Sep 28."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21775560;DERIVED;"Kesse-Guyot E, Fezeu L, Jeandel C, Ferry M, Andreeva V, Amieva H, Hercberg S, Galan P. French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial. Am J Clin Nutr. 2011 Sep;94(3):892-9. doi: 10.3945/ajcn.110.007815. Epub 2011 Jul 20."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21490142;DERIVED;"Perez-Jimenez J, Fezeu L, Touvier M, Arnault N, Manach C, Hercberg S, Galan P, Scalbert A. Dietary intake of 337 polyphenols in French adults. Am J Clin Nutr. 2011 Jun;93(6):1220-8. doi: 10.3945/ajcn.110.007096. Epub 2011 Apr 13."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21106918;DERIVED;"Kesse-Guyot E, Amieva H, Castetbon K, Henegar A, Ferry M, Jeandel C, Hercberg S, Galan P; SU.VI.MAX 2 Research Group. Adherence to nutritional recommendations and subsequent cognitive performance: findings from the prospective Supplementation with Antioxidant Vitamins and Minerals 2 (SU.VI.MAX 2) study. Am J Clin Nutr. 2011 Jan;93(1):200-10. doi: 10.3945/ajcn.2010.29761. Epub 2010 Nov 24."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;20605091;DERIVED;"Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D. Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer. 2010 Dec;46(18):3316-22. doi: 10.1016/j.ejca.2010.06.008. Epub 2010 Jul 6."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;20431391;DERIVED;"Kesse-Guyot E, Vergnaud AC, Fezeu L, Zureik M, Blacher J, Peneau S, Hercberg S, Galan P, Czernichow S. Associations between dietary patterns and arterial stiffness, carotid artery intima-media thickness and atherosclerosis. Eur J Cardiovasc Prev Rehabil. 2010 Dec;17(6):718-24. doi: 10.1097/HJR.0b013e32833a197f."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;20176858;DERIVED;"Phillips CM, Goumidi L, Bertrais S, Field MR, Cupples LA, Ordovas JM, Defoort C, Lovegrove JA, Drevon CA, Gibney MJ, Blaak EE, Kiec-Wilk B, Karlstrom B, Lopez-Miranda J, McManus R, Hercberg S, Lairon D, Planells R, Roche HM. Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. J Lipid Res. 2010 Jul;51(7):1793-800. doi: 10.1194/jlr.M003046. Epub 2010 Feb 22."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;19828715;DERIVED;"Phillips CM, Goumidi L, Bertrais S, Ferguson JF, Field MR, Kelly ED, Peloso GM, Cupples LA, Shen J, Ordovas JM, McManus R, Hercberg S, Portugal H, Lairon D, Planells R, Roche HM. Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. Am J Clin Nutr. 2009 Dec;90(6):1665-73. doi: 10.3945/ajcn.2009.28101. Epub 2009 Oct 14."
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;19491388;DERIVED;"Czernichow S, Vergnaud AC, Galan P, Arnaud J, Favier A, Faure H, Huxley R, Hercberg S, Ahluwalia N. Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. Am J Clin Nutr. 2009 Aug;90(2):329-35. doi: 10.3945/ajcn.2009.27635. Epub 2009 Jun 2."
NCT02052271;Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-03;2014-06-03;2018-03-27;;;
NCT01534728;Identification of Hepatitis C Virus (HCV) Specific T Cells;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-17;2012-02;2014-03;;;
NCT01492985;Lipopeptide Immunisation With GTU-multiHIV Trial;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-12-15;2013-07;2017-04-08;33568510;DERIVED;"Levy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, Foucat E, Surenaud M, Guillaumat L, Boilet V, Rieux V, Bouchaud O, Girard PM, Molina JM, Morlat P, Hocqueloux L, Richert L, Pantaleo G, Lelievre JD, Thiebaut R. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. J Virol. 2021 Apr 12;95(9):e02165-20. doi: 10.1128/JVI.02165-20. Print 2021 Apr 12."
NCT00120185;Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119);French National Agency for Research on AIDS and Viral Hepatitis;Chiron Corporation;COMPLETED;INTERVENTIONAL;False;2005-07-15;2003-12;2006-11;19508157;DERIVED;"Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) 119 Interstart Study Team. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis. 2009 Jul 15;200(2):206-15. doi: 10.1086/599989."
NCT01463956;Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-11-02;2012-01-06;2015-01-22;;;
NCT00334256;Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA);French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-06-07;2006-10;2009-12;19307941;RESULT;"TEmAA ANRS 12109 Study group; Arrive E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouevi DK, Dabis F. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS. 2009 Apr 27;23(7):825-33. doi: 10.1097/QAD.0b013e32832949d5."
NCT00334256;Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA);French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-06-07;2006-10;2009-12;19104016;RESULT;"Hirt D, Urien S, Rey E, Arrive E, Ekouevi DK, Coffie P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Treluyer JM. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2009 Mar;53(3):1067-73. doi: 10.1128/AAC.00860-08. Epub 2008 Dec 22."
NCT00334256;Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA);French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-06-07;2006-10;2009-12;18987623;RESULT;"Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Treluyer JM; ANRS 12109. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009 Feb;85(2):182-9. doi: 10.1038/clpt.2008.201. Epub 2008 Nov 5."
NCT00822315;Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2009-01-14;2009-07;2012-05;24726095;DERIVED;"Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chene G, Molina JM; ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9. Erratum In: Lancet Infect Dis. 2014 Jun;14(6):448."
NCT04120415;A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02);ANRS, Emerging Infectious Diseases;EuroVacc Foundation | European AIDS Treatment Group (EATG) | Medical Research Council | University College London Hospitals | University of Liverpool | Erasmus Medical Center | Henri Mondor University Hospital | European Georges Pompidou Hospital | Saint-Louis Hospital, Paris, France | Centre Hospitalier Universitaire Vaudois | Chelsea and Westminster Hospital, UK | Universitätsklinikum Hamburg-Eppendorf | Hospital Clinic of Barcelona | Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Imperial College London | Institut d'Investigacions Biomèdiques August Pi i Sunyer | European Commission | Swiss Government;COMPLETED;INTERVENTIONAL;False;2019-10-09;2022-06-21;2023-07-12;;;
NCT02567071;Natural Microbiota Restoration After C-section Birth;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-10-02;2016-04-06;2019-04;;;
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;31455612;DERIVED;"Marcy O, Borand L, Ung V, Msellati P, Tejiokem M, Huu KT, Do Chau V, Ngoc Tran D, Ateba-Ndongo F, Tetang-Ndiang S, Nacro B, Sanogo B, Neou L, Goyet S, Dim B, Pean P, Quillet C, Fournier I, Berteloot L, Carcelain G, Godreuil S, Blanche S, Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP. A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis. Pediatrics. 2019 Sep;144(3):e20182065. doi: 10.1542/peds.2018-2065."
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;30689814;DERIVED;"Borand L, de Lauzanne A, Nguyen NL, Cheng S, Pham TH, Eyangoh S, Ouedraogo AS, Ung V, Msellati P, Tejiokem M, Nacro B, Inghammar M, Dim B, Delacourt C, Godreuil S, Blanche S, Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group. Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis. Clin Infect Dis. 2019 May 2;68(10):1750-1753. doi: 10.1093/cid/ciy897."
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;29174612;DERIVED;"Marcy O, Tejiokem M, Msellati P, Truong Huu K, Do Chau V, Tran Ngoc D, Nacro B, Ateba-Ndongo F, Tetang-Ndiang S, Ung V, Dim B, Neou L, Berteloot L, Borand L, Delacourt C, Blanche S; ANRS 12229 PAANTHER 01 Study Group. Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study. Lancet HIV. 2018 Feb;5(2):e87-e95. doi: 10.1016/S2352-3018(17)30206-0. Epub 2017 Nov 23."
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;26908804;DERIVED;"Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, Delacourt C. Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children. Clin Infect Dis. 2016 May 1;62(9):1161-1168. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7."
NCT02214511;Biomarkers of Social Sensitivity in Major Depression;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-08-12;2014-10-23;2017-03-01;;;
NCT01698411;Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-03;2012-10;2015-02;;;
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;;;
NCT02157311;4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-06-06;2014-07;2016-01;29186458;DERIVED;"de Truchis P, Assoumou L, Landman R, Mathez D, Le Du D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434."
NCT02082171;Multidomain Intervention to Prevent Disability in Elders;Institut National de la Santé Et de la Recherche Médicale, France;National Research Agency, France;COMPLETED;INTERVENTIONAL;False;2014-03-10;2013-10-16;2016-01-27;;;
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;34611902;DERIVED;"Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4."
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;29329763;DERIVED;"Mercie P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, Duvivier C, Reynes J, Wirth N, Moinot L, Benard A, Zucman D, Duval X, Molina JM, Spire B, Fagard C, Chene G; ANRS 144 Inter-ACTIV study group. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. Lancet HIV. 2018 Mar;5(3):e126-e135. doi: 10.1016/S2352-3018(18)30002-X. Epub 2018 Jan 9."
NCT05090956;Developpement of 3T MRI Protocol;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-10-25;2012-06-08;2020-01-29;;;
NCT02346409;Cerebello-thalamo-cortical Coupling in Essential Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-01-27;2015-02-04;2018-02-16;;;
NCT00196599;Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults;French National Agency for Research on AIDS and Viral Hepatitis;Triangle Pharmaceuticals | Gilead Sciences | Bristol-Myers Squibb | Dupont Applied Biosciences;COMPLETED;INTERVENTIONAL;False;2005-09-20;1999-02;2004-09;10915095;RESULT;"Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM, Chene G. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000 Aug;182(2):599-602. doi: 10.1086/315711. Epub 2000 Jul 13."
NCT00196599;Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults;French National Agency for Research on AIDS and Viral Hepatitis;Triangle Pharmaceuticals | Gilead Sciences | Bristol-Myers Squibb | Dupont Applied Biosciences;COMPLETED;INTERVENTIONAL;False;2005-09-20;1999-02;2004-09;15012649;RESULT;"Molina JM, Peytavin G, Perusat S, Lascoux-Combes C, Sereni D, Rozenbaum W, Chene G. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. 2004 Mar;5(2):99-104. doi: 10.1111/j.1468-1293.2004.00194.x."
NCT02102737;Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-03;2014-05-13;2018-03;;;
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21576452;RESULT;"Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM, Molina JM. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother. 2011 Jul;55(7):3613-5. doi: 10.1128/AAC.01827-10. Epub 2011 May 16."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;19995925;RESULT;"Barau C, Delaugerre C, Braun J, de Castro N, Furlan V, Charreau I, Gerard L, Lascoux-Combe C, Molina JM, Taburet AM. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;20683319;RESULT;"Delaugerre C, Charreau I, Braun J, Nere ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F; ANRS 138 study group. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS. 2010 Sep 24;24(15):2391-5. doi: 10.1097/QAD.0b013e32833d214c."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21126958;RESULT;"Boulet T, Pavie J, Charreau I, Braun J, Reynes J, Morlat P, Piroth L, Spire B, Molina JM, Aboulker JP; Easier-Anrs 138 Study Group. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin Trials. 2010 Sep-Oct;11(5):283-93. doi: 10.1310/hct1105-283."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21326075;RESULT;"Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DR. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS. 2011 Mar 13;25(5):665-9. doi: 10.1097/QAD.0b013e3283445834."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21712241;RESULT;"Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;22416781;RESULT;"Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP; ANRS 138-EASIER study group. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med. 2012 Oct;13(9):517-25. doi: 10.1111/j.1468-1293.2012.01002.x. Epub 2012 Mar 14."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;27042193;DERIVED;"de Castro N, Braun J, Charreau I, Lafeuillade A, Viard JP, Allavena C, Aboulker JP, Molina JM; EASIER ANRS 138 study group. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Res Ther. 2016 Apr 2;13:17. doi: 10.1186/s12981-016-0101-3. eCollection 2016."
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;19757993;DERIVED;"De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674."
NCT02656407;Intraoperative Functional Ultrasound;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-15;2016-02-11;2018-02;25955583;BACKGROUND;"Demene C, Deffieux T, Pernot M, Osmanski BF, Biran V, Gennisson JL, Sieu LA, Bergel A, Franqui S, Correas JM, Cohen I, Baud O, Tanter M. Spatiotemporal Clutter Filtering of Ultrafast Ultrasound Data Highly Increases Doppler and fUltrasound Sensitivity. IEEE Trans Med Imaging. 2015 Nov;34(11):2271-85. doi: 10.1109/TMI.2015.2428634. Epub 2015 Apr 30."
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;16044019;RESULT;"Nagot N, Foulongne V, Becquart P, Mayaud P, Konate I, Ouedraogo A, Defer MC, Weiss H, Van de Perre P, Segondy M. Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):632-4."
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;18596069;DERIVED;"Mayaud P, Nagot N, Konate I, Ouedraogo A, Weiss HA, Foulongne V, Defer MC, Sawadogo A, Segondy M, Van de Perre P; ANRS 1285 Study Group. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect. 2008 Oct;84(5):332-7. doi: 10.1136/sti.2008.030692. Epub 2008 Jul 2."
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;18593294;DERIVED;"Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, Sanon A, Becquart P, Segondy M, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. 2008 Jul 15;198(2):241-9. doi: 10.1086/589621."
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;17314338;DERIVED;"Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, Defer MC, Djagbare D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007 Feb 22;356(8):790-9. doi: 10.1056/NEJMoa062607."
NCT02038842;Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-01-17;2014-03;2016-03;;;
NCT01725542;Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2012-11-14;2012-12;2014-06;25977266;DERIVED;"Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. Clin Infect Dis. 2015 Sep 1;61(5):817-25. doi: 10.1093/cid/civ381. Epub 2015 May 14."
NCT06260319;Decoding Developmental Disorders in Humams;Institut National de la Santé Et de la Recherche Médicale, France;Imagine Institute | Commissariat A L'energie Atomique;COMPLETED;OBSERVATIONAL;False;2024-02-15;2019-01-01;2024-01-01;;;
NCT01842919;Dance and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-30;2013-04;2016-07-08;;;
NCT02906137;Gut-Associated Lymphocyte Trafficking;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-09-19;2017-02-06;2020-02-25;;;
NCT01192737;"""COhort Study on A/H1N1 FLU During PREGnancy""";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2010-09-01;2009-10;2010-11;;;
NCT02647632;Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-01-06;2016-01;2017-04;29077864;DERIVED;"de Ledinghen V, Laforest C, Hezode C, Pol S, Renault A, Alric L, Larrey D, Metivier S, Tran A, Jezequel C, Samuel D, Zoulim F, Tual C, Pailhe A, Gibowski S, Bourliere M, Bellissant E, Pawlotsky JM. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916."
NCT01065207;Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-02-09;2009-03;2012-03;;;
NCT02542800;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2017-06-02;;;
NCT01089400;Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris | Institut Pasteur;COMPLETED;OBSERVATIONAL;False;2010-03-18;2009-10;2011-04;24646009;DERIVED;"Guihot A, Luyt CE, Parrot A, Rousset D, Cavaillon JM, Boutolleau D, Fitting C, Pajanirassa P, Mallet A, Fartoukh M, Agut H, Musset L, Zoorob R, Kirilovksy A, Combadiere B, van der Werf S, Autran B, Carcelain G; FluBAL Study Group. Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection. Am J Respir Crit Care Med. 2014 May 15;189(10):1240-9. doi: 10.1164/rccm.201311-2071OC."
NCT00574652;Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-12-17;2008-03;2010-09;22129253;DERIVED;"Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum In: N Engl J Med. 2014 Feb 20;370(8):786."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16249701;BACKGROUND;"Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, Gonzalez-Garcia JJ, Cepeda C, Hervas R, Pano JR, Gaya F, Carcas A, Montes ML, Costa JR, Pena JM. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18097218;BACKGROUND;"Pulido F, Arribas JR, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M; OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008 Jan 11;22(2):F1-9. doi: 10.1097/QAD.0b013e3282f4243b."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18540803;BACKGROUND;"Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008 Jul 15;198(2):234-40. doi: 10.1086/589622."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21886816;BACKGROUND;"Cahn P, Montaner J, Junod P, Patterson P, Krolewiecki A, Andrade-Villanueva J, Cassetti I, Sierra-Madero J, Casiro AD, Bortolozzi R, Lupo SH, Longo N, Rampakakis E, Ackad N, Sampalis JS. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. PLoS One. 2011;6(8):e23726. doi: 10.1371/journal.pone.0023726. Epub 2011 Aug 19."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;17545707;BACKGROUND;"Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007 Jun 19;21(10):1309-15. doi: 10.1097/QAD.0b013e32814e6b1c."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802298;BACKGROUND;"Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, Cavassini M, Yerly S, Vernazza PL; Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010 Sep 24;24(15):2347-54. doi: 10.1097/QAD.0b013e32833db9a1."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802297;BACKGROUND;"Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010 Sep 24;24(15):2365-74. doi: 10.1097/QAD.0b013e32833dec20."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20010070;BACKGROUND;"Arribas JR, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21811554;BACKGROUND;"Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, Vernazza P, Cahn P, Meynard JL, Arribas J, Bucher HC. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003. doi: 10.1371/journal.pone.0022003. Epub 2011 Jul 19."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22814125;BACKGROUND;"Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22441252;BACKGROUND;"Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16549962;BACKGROUND;"Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006 Apr 4;20(6):795-803. doi: 10.1097/01.aids.0000218542.08845.b2."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;23075703;BACKGROUND;"Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Erratum In: Antivir Ther. 2012;17(7):1389-90."
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;28566227;DERIVED;"Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28."
NCT02125500;Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-04-29;2014-08;2015-12;;;
NCT01413152;Residual Risk Assessment Of HIV Transmission;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-10;2011-07;2012-03;;;
NCT02236832;Study of the Neural Basis of Analogical Reasoning;Institut National de la Santé Et de la Recherche Médicale, France;Fondation pour la Recherche Médicale;COMPLETED;INTERVENTIONAL;False;2014-09-11;2015-02;2021-02;;;
NCT00115609;Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-06-24;2006-01;2009-11;;;
NCT04396288;Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-05-20;2021-09-14;2024-01-30;;;
NCT00445575;Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone;Institut National de la Santé Et de la Recherche Médicale, France;ZonMw: The Netherlands Organisation for Health Research and Development | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Charite University, Berlin, Germany;COMPLETED;INTERVENTIONAL;False;2007-03-09;2007-07-22;2017-12-07;;;
NCT01024400;Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women;Institut National de la Santé Et de la Recherche Médicale, France;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2009-12-02;2009-11;2010-07;22147712;DERIVED;"Tsatsaris V, Capitant C, Schmitz T, Chazallon C, Bulifon S, Riethmuller D, Picone O, Poulain P, Lewin F, Laine F, Jacqz-Aigrain E, Aboulker JP, Launay O; Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial. Ann Intern Med. 2011 Dec 6;155(11):733-41. doi: 10.7326/0003-4819-155-11-201112060-00005."
NCT01779752;Vestibular Cortex and TMS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-01-20;2016-01;;;
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;31320358;DERIVED;"Coste M, De Seze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group. Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). BMJ Open. 2019 Jul 17;9(7):e030211. doi: 10.1136/bmjopen-2019-030211."
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;36068621;DERIVED;"Whitfield T, Demnitz-King H, Schlosser M, Barnhofer T, Frison E, Coll-Padros N, Dautricourt S, Requier F, Delarue M, Gonneaud J, Klimecki OM, Lutz A, Paly L, Salmon E, Schild AK, Walker Z, Jessen F, Chetelat G, Collette F, Wirth M, Marchant NL; Medit-Ageing Research Group. Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial. Alzheimers Res Ther. 2022 Sep 6;14(1):125. doi: 10.1186/s13195-022-01057-w."
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;35853750;DERIVED;"Demnitz-King H, Gonneaud J, Klimecki OM, Chocat A, Collette F, Dautricourt S, Jessen F, Krolak-Salmon P, Lutz A, Morse RM, Molinuevo JL, Poisnel G, Touron E, Wirth M, Walker Z, Chetelat G, Marchant NL; Medit-Ageing Research Group. Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults. Neurology. 2022 Sep 27;99(13):e1422-e1431. doi: 10.1212/WNL.0000000000200951. Epub 2022 Jul 19."
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;33873195;DERIVED;"Marchant NL, Barnhofer T, Coueron R, Wirth M, Lutz A, Arenaza-Urquijo EM, Collette F, Poisnel G, Demnitz-King H, Schild AK, Coll-Padros N, Delphin-Combe F, Whitfield T, Schlosser M, Gonneaud J, Asselineau J, Walker Z, Krolak-Salmon P, Molinuevo JL, Frison E, Chetelat G, Jessen F, Klimecki OM; The Medit-Ageing Research Group. Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychother Psychosom. 2021;90(5):341-350. doi: 10.1159/000515669. Epub 2021 Apr 19."
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;33657112;RESULT;"Funk AL, Hoen B, Vingdassalom I, Ryan C, Kadhel P, Schepers K, Gaete S, Tressieres B, Fontanet A. Reassessment of the risk of birth defects due to Zika virus in Guadeloupe, 2016. PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009048. doi: 10.1371/journal.pntd.0009048. eCollection 2021 Mar."
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;29539287;RESULT;"Hoen B, Schaub B, Funk AL, Ardillon V, Boullard M, Cabie A, Callier C, Carles G, Cassadou S, Cesaire R, Douine M, Herrmann-Storck C, Kadhel P, Laouenan C, Madec Y, Monthieux A, Nacher M, Najioullah F, Rousset D, Ryan C, Schepers K, Stegmann-Planchard S, Tressieres B, Volumenie JL, Yassinguezo S, Janky E, Fontanet A. Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas. N Engl J Med. 2018 Mar 15;378(11):985-994. doi: 10.1056/NEJMoa1709481."
NCT01311752;Study of Human Papillomavirus Related Genital Pathology Among HIV Positive Women;French National Agency for Research on AIDS and Viral Hepatitis;Virology study Heather A Cubie Catherine Moore Edinburg United Kingdom | Anatomopathology study Christine Bergeron Laboratoire Pasteur Cerba Cergy Pontoise France | Paris, Isabelle Cartier, M.D. | Immunology study Guislaine Carcelain Groupe Hospitalier Pitié Salpétrière Paris | Surgery study Hervé Foulot Cochin Paris;COMPLETED;OBSERVATIONAL;False;2011-03-09;2007-11;2012-12;;;
NCT01269632;Cohort of Young Adults Infected With HIV Since Birth or During Childhood;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-01-04;2010-06;2018-12-27;;;
NCT01495897;Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-20;2011-03;2014-03;;;
NCT00463983;Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-04-20;2006-10;2012-01;16883006;BACKGROUND;"Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, Marchal J, Raguin O, Gruaz-Guyon A, Reubi JC, Le Guludec D, Crestani B. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med. 2006 Aug;47(8):1281-7."
NCT00463983;Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-04-20;2006-10;2012-01;22379151;DERIVED;"Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, Israel-Biet D, Lacronique J, Monnet I, Reynaud-Gaubert M, Tazi A, Lebtahi R, Debray MP, Brauner M, Dehoux M, Dornic Q, Aubier M, Mentre F, Duval X. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J. 2012 Mar;39(3):772-5. doi: 10.1183/09031936.00113011. No abstract available."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22267473;BACKGROUND;"Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C; ANRS COPANA Cohort Study Group. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22008658;BACKGROUND;"Dray-Spira R, Legeai C, Le Den M, Boue F, Lascoux-Combe C, Simon A, May T, Goujard C, Meyer L; ANRS-COPANA Cohort Study Group. Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use. AIDS. 2012 Jan 14;26(2):207-15. doi: 10.1097/QAD.0b013e32834dcf61."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23079802;BACKGROUND;"Rachas A, Warszawski J, Le Chenadec J, Legeai C, Teglas JP, Goujard C, Rouzioux C, Mandelbrot L, Tubiana R, Meyer L. Does pregnancy affect the early response to cART? AIDS. 2013 Jan 28;27(3):357-67. doi: 10.1097/QAD.0b013e32835ac8bc."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23936509;BACKGROUND;"Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum In: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added]."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24058636;BACKGROUND;"Legeai C, Vigouroux C, Souberbielle JC, Bouchaud O, Boufassa F, Bastard JP, Carlier R, Capeau J, Goujard C, Meyer L, Viard JP; ANRS-COPANA Cohort Study Group. Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 <<COPANA>> cohort study. PLoS One. 2013 Sep 18;8(9):e74868. doi: 10.1371/journal.pone.0074868. eCollection 2013."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24465584;BACKGROUND;"Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014 Jan 17;9(1):e85516. doi: 10.1371/journal.pone.0085516. eCollection 2014."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;25573889;BACKGROUND;"El Khoury P, Ghislain M, Villard EF, Le Goff W, Lascoux-Combe C, Yeni P, Meyer L, Vigouroux C, Goujard C, Guerin M. Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART. J Lipid Res. 2015 Mar;56(3):692-702. doi: 10.1194/jlr.M054510. Epub 2015 Jan 8."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;26636578;BACKGROUND;"Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gerard L, May T, Simon A, Vigouroux C, Goujard C; ANRS-COPANA Cohort Study Group. Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities. PLoS One. 2015 Dec 4;10(12):e0144317. doi: 10.1371/journal.pone.0144317. eCollection 2015."
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;27509048;BACKGROUND;"Ploquin MJ, Madec Y, Casrouge A, Huot N, Passaes C, Lecuroux C, Essat A, Boufassa F, Jacquelin B, Jochems SP, Petitjean G, Angin M, Gartner K, Garcia-Tellez T, Noel N, Booiman T, Boeser-Nunnink BD, Roques P, Saez-Cirion A, Vaslin B, Dereudre-Bosquet N, Barre-Sinoussi F, Ghislain M, Rouzioux C, Lambotte O, Albert ML, Goujard C, Kootstra N, Meyer L, Muller-Trutwin MC. Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathog. 2016 Aug 10;12(8):e1005774. doi: 10.1371/journal.ppat.1005774. eCollection 2016 Aug."
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;35264424;DERIVED;"Wilke C, Mengel D, Schols L, Hengel H, Rakowicz M, Klockgether T, Durr A, Filla A, Melegh B, Schule R, Reetz K, Jacobi H, Synofzik M. Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. Neurology. 2022 May 17;98(20):e1985-e1996. doi: 10.1212/WNL.0000000000200257. Epub 2022 Mar 9."
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;32822634;DERIVED;"Jacobi H, du Montcel ST, Romanzetti S, Harmuth F, Mariotti C, Nanetti L, Rakowicz M, Makowicz G, Durr A, Monin ML, Filla A, Roca A, Schols L, Hengel H, Infante J, Kang JS, Timmann D, Casali C, Masciullo M, Baliko L, Melegh B, Nachbauer W, Burk-Gergs K, Schulz JB, Riess O, Reetz K, Klockgether T. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurol. 2020 Sep;19(9):738-747. doi: 10.1016/S1474-4422(20)30235-0."
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;24780882;DERIVED;"Tezenas du Montcel S, Durr A, Rakowicz M, Nanetti L, Charles P, Sulek A, Mariotti C, Rola R, Schols L, Bauer P, Dufaure-Gare I, Jacobi H, Forlani S, Schmitz-Hubsch T, Filla A, Timmann D, van de Warrenburg BP, Marelli C, Kang JS, Giunti P, Cook A, Baliko L, Melegh B, Boesch S, Szymanski S, Berciano J, Infante J, Buerk K, Masciullo M, Di Fabio R, Depondt C, Ratka S, Stevanin G, Klockgether T, Brice A, Golmard JL. Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. J Med Genet. 2014 Jul;51(7):479-86. doi: 10.1136/jmedgenet-2013-102200. Epub 2014 Apr 29. Erratum In: J Med Genet. 2014 Sep;51(9):613. Bela, Melegh [corrected to Melegh, Bela]."
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;23707147;DERIVED;"Jacobi H, Reetz K, du Montcel ST, Bauer P, Mariotti C, Nanetti L, Rakowicz M, Sulek A, Durr A, Charles P, Filla A, Antenora A, Schols L, Schicks J, Infante J, Kang JS, Timmann D, Di Fabio R, Masciullo M, Baliko L, Melegh B, Boesch S, Burk K, Peltz A, Schulz JB, Dufaure-Gare I, Klockgether T. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 2013 Jul;12(7):650-8. doi: 10.1016/S1474-4422(13)70104-2. Epub 2013 May 22. Erratum In: Lancet Neurol. 2013 Jul;12(7):630."
NCT01842477;Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-29;2013-05;2016-02-05;;;
NCT02721745;Cause and Consequence of Neural Fatigue;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-03-29;2016-05-23;2020-12;;;
NCT02408354;Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-03;2015-04-15;2017-04-05;28969699;DERIVED;"Hainque E, Caillet S, Leroy S, Flamand-Roze C, Adanyeguh I, Charbonnier-Beaupel F, Retail M, Le Toullec B, Atencio M, Rivaud-Pechoux S, Brochard V, Habarou F, Ottolenghi C, Cormier F, Meneret A, Ruiz M, Doulazmi M, Roubergue A, Corvol JC, Vidailhet M, Mochel F, Roze E. A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood. Orphanet J Rare Dis. 2017 Oct 2;12(1):160. doi: 10.1186/s13023-017-0713-2."
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;34087324;DERIVED;"Manneville F, Omorou AY, Legrand K, Lecomte E, Rydberg JA, Briancon S, Guillemin F; PRALIMAP Trial Group. Sociodemographic and psychological characteristics associated with discrepancy between body satisfaction and weight change among adolescents. Prev Med. 2021 Sep;150:106668. doi: 10.1016/j.ypmed.2021.106668. Epub 2021 Jun 1."
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;32097754;DERIVED;"Omorou AY, Manneville F, Langlois J, Legrand K, Bohme P, Muller L, Guillemin F, Briancon S, Lecomte E; PRALIMAP-INES Trial Group. Physical activity rather than sedentary behaviour is socially determined in French adolescents with overweight and obesity. Prev Med. 2020 May;134:106043. doi: 10.1016/j.ypmed.2020.106043. Epub 2020 Feb 22."
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29934380;DERIVED;"Saez L, Legrand K, Alleyrat C, Ramisasoa S, Langlois J, Muller L, Omorou AY, De Lavenne R, Kivits J, Lecomte E, Briancon S; PRALIMAP-INES Trial Group. Using facilitator-receiver peer dyads matched according to socioeconomic status to promote behaviour change in overweight adolescents: a feasibility study. BMJ Open. 2018 Jun 22;8(6):e019731. doi: 10.1136/bmjopen-2017-019731."
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29776897;DERIVED;"Saez L, Langlois J, Legrand K, Quinet MH, Lecomte E, Omorou AY, Briancon S; PRALIMAP-INES Trial Group. Reach and Acceptability of a Mobile Reminder Strategy and Facebook Group Intervention for Weight Management in Less Advantaged Adolescents: Insights From the PRALIMAP-INES Trial. JMIR Mhealth Uhealth. 2018 May 18;6(5):e110. doi: 10.2196/mhealth.7657."
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29696179;DERIVED;"Legrand K, Lecomte E, Langlois J, Muller L, Saez L, Quinet MH, Bohme P, Spitz E, Omorou AY, Briancon S; PRALIMAP-INES trial group. Reducing social inequalities in access to overweight and obesity care management for adolescents: The PRALIMAP-INES trial protocol and inclusion data analysis. Contemp Clin Trials Commun. 2017 Jun 16;7:141-157. doi: 10.1016/j.conctc.2017.05.010. eCollection 2017 Sep."
NCT02172677;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2014-06-24;2014-10;2016-10-14;;;
NCT01880151;Neuroelectrical Biomarkers for Alzheimer's Disease Stages;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-06-18;2013-07-12;2019-01;;;
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;33717176;DERIVED;"Gamain B, Chene A, Viebig NK, Tuikue Ndam N, Nielsen MA. Progress and Insights Toward an Effective Placental Malaria Vaccine. Front Immunol. 2021 Feb 25;12:634508. doi: 10.3389/fimmu.2021.634508. eCollection 2021."
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;32032566;DERIVED;"Sirima SB, Richert L, Chene A, Konate AT, Campion C, Dechavanne S, Semblat JP, Benhamouda N, Bahuaud M, Loulergue P, Ouedraogo A, Nebie I, Kabore M, Kargougou D, Barry A, Ouattara SM, Boilet V, Allais F, Roguet G, Havelange N, Lopez-Perez E, Kuppers A, Konate E, Roussillon C, Kante M, Belarbi L, Diarra A, Henry N, Soulama I, Ouedraogo A, Esperou H, Leroy O, Batteux F, Tartour E, Viebig NK, Thiebaut R, Launay O, Gamain B. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis. 2020 May;20(5):585-597. doi: 10.1016/S1473-3099(19)30739-X. Epub 2020 Feb 4."
NCT02027051;Etude génétique Des Arméniens;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-01-03;2014-01;2017-01;;;
NCT00118677;Long-Term Supervised Treatment Interruption in HIV-Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-12;2003-02;2007-05;20657770;DERIVED;"Weiss L, Piketty C, Assoumou L, Didier C, Caccavelli L, Donkova-Petrini V, Levy Y, Girard PM, Burgard M, Viard JP, Rouzioux C, Costagliola D; ANRS 116 SALTO study group. Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PLoS One. 2010 Jul 21;5(7):e11659. doi: 10.1371/journal.pone.0011659."
NCT00647205;Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-03-31;2008-01;2010-11;;;
